THE USE OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS: 
Principles and Current Evidence

A Consensus Paper by the Multiple Sclerosis Coalition

Updated June 2019 
Original July 2014
DISCLOSURES

2019 Revision - Writing Team

Kathleen Costello, MS, ANP-BC, MSCN – Nothing to disclose
Rosalind Kalb, PhD – Consultant: Sanofi-Genzyme and Novartis Pharmaceuticals

Reviewers

Jack Antel, MD\textsuperscript{a} – Advisory and/or data safety monitoring board: Biogen, Medday Laboratory support through McGill University: Mallinckrodt, Revalesio, Medday, Roche (Canada); Multiple Sclerosis Journal: Co-Editor for the Americas.

Brenda Banwell, MD\textsuperscript{b} – Non-remunerated consultant: Biogen, Novartis Pharmaceuticals, Sanofi US; Central MRI reviewer for prior trial for Novartis; Grant Support: National Multiple Sclerosis Society, Canadian Multiple Sclerosis Scientific Research Foundation.

Aliza Ben-Zacharia, DrNP, ANP, MSCN\textsuperscript{a} – Consultant: Biogen, EMD Serono, Novartis Pharmaceuticals, Genentech, Genzyme Corporation; Grant support: Biogen, Novartis Pharmaceuticals.

James Bowen, MD\textsuperscript{a} – Consultant: Biogen, Celgene, EMD Serono, Genentech, Novartis; Speaker: Biogen, EMD Serono, Genentech, Novartis; Grant support: Abbvie, Alkermes, Biogen, Celgene, Genzyme, Genentech, Novartis, TG Therapeutics; Shareholder: Amgen.

Bruce Cohen, MD\textsuperscript{a} – Consultant: Biogen, EMD Serono, Celgene; Funded Institutional Research through Northwestern University, Novartis Pharmaceuticals, Genentech / Hoffman La Roche, MedDay.

Bruce Cree, MD, PhD\textsuperscript{b} – Consultant: Abbvie, Biogen, EMD Serono, Genzyme Corporation, Aventis, MedImmune, Novartis Pharmaceuticals, Teva Pharmaceuticals; Grant/research support (including clinical trials): Acorda Therapeutics, Avanir Pharmaceuticals, Biogen, EMD Serono, Hoffman La Roche, Novartis Pharmaceuticals.

Suhayl Dhib-Jalbut, MD\textsuperscript{a} – Grant support: Teva Pharmaceuticals, Biogen, Bayer.

David E. Jones, MD\textsuperscript{c} – Past consultant: Biogen, Genzyme Corporation, Novartis Pharmaceuticals; Past grant support: National Multiple Sclerosis Society, Biogen.

Daniel Kantor, MD\textsuperscript{d} – Consultant: Actelion Pharmaceuticals, Avanir Pharmaceuticals, Biogen, Celgene Corporation, Genzyme Corporation, Mylan, Novartis Pharmaceuticals, Osmotica Pharmaceutical; Speaker: Avanir Pharmaceuticals, Biogen, Genzyme Corporation, Novartis Pharmaceuticals; Grant support: Actelion Pharmaceuticals, Biogen, Genzyme Corporation, Novartis Pharmaceuticals.

Flavia Nelson, MD\textsuperscript{b} – Consultant for Advisory Boards or Speaker: Biogen, Novartis Pharmaceuticals, Teva Pharmaceuticals, Bayer HealthCare, Mallinckrodt, Genzyme Corporation; Grant support: National Institutes of Health.

Nancy Sicotte, MD\textsuperscript{e} – Grant support: National Multiple Sclerosis Society, Guthy-Jackson Charitable Foundation, Race to Erase MS, Patient-Centered Outcomes Research Institute (PCORI).

\textsuperscript{a}Reviewed original, March 2015, July 2016, March 2017, September 2018, June 2019 updates
\textsuperscript{b}Reviewed original only
\textsuperscript{c}Reviewed March 2015, July 2016, March 2017 updates
\textsuperscript{d}Reviewed original, March 2015, July 2016, September 2018, June 2019 updates
\textsuperscript{e}Reviewed original, March 2015, July 2016, March 2017, September 2018 updates
Original Writing and Development Team

Kathleen Costello, MS, ANP-BC, MSCN – Nothing to disclose
June Halper, MSN, APN-C, MSCN, FAAN – Nothing to disclose
Rosalind Kalb, PhD – Nothing to disclose
Lisa Skutnik, PT, MA, MA – Consultant: Biogen, Sanofi-Genzyme
Robert Rapp, MPA* – Nothing to disclose

*deceased
THE USE OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS: Principles and Current Evidence
A Consensus Paper by the Multiple Sclerosis Coalition

ABSTRACT

Purpose: The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States.

Development Process: The original writing and development team comprised of professional staff representing the Coalition organizations (Rosalind Kalb, Kathleen Costello, June Halper, Lisa Skutnik and Robert Rapp) developed a draft for review and input by nine external reviewers (Brenda Banwell, Aliza Ben-Zacharia, James Bowen, Bruce Cohen, Bruce Cree, Suhayl Dhib-Jalbut, Daniel Kantor, Flavia Nelson and Nancy Sicotte). The reviewers, selected for their experience and expertise in MS clinical care and research, were charged with ensuring the accuracy, completeness and fair balance of the content. The revised paper was then submitted for review by the medical advisors of the Coalition member organizations. The final paper, incorporating feedback from these advisors, was endorsed by all Coalition members, and subsequently by Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), and published in November 2014.

Updates with Reviews by External Reviewers and ACTRIMS for their Endorsement:
- March 2015
- July 2016
- March 2017
- September 2018
- June 2019

Conclusions: Based on a comprehensive review of the current evidence, the Multiple Sclerosis Coalition* states the following:

Treatment Considerations:
- Initiation of treatment with an FDA-approved disease-modifying therapy is recommended:
  - As soon as possible following a diagnosis of relapsing multiple sclerosis, regardless of the person’s age. Relapsing MS includes:
    ▪ clinically isolated syndrome (CIS): People with a first clinical event and MRI features consistent with MS in whom other possible causes have been excluded
    ▪ relapsing-remitting MS
    ▪ active secondary progressive MS with clinical relapses or inflammatory activity on MRI.
  - For individuals with primary progressive multiple sclerosis, with an agent approved for this phenotype
- Clinicians should consider prescribing a high efficacy medication such as alemtuzumab, cladribine, fingolimod, natalizumab or ocrelizumab for newly diagnosed individuals with highly active MS.
- Clinicians should also consider prescribing a high efficacy medication for individuals who have breakthrough activity on another disease-modifying therapy, regardless of the number of previously used agents.

*The Multiple Sclerosis Coalition was founded in 2005 to increase opportunities for cooperation and provide greater opportunity to leverage the effective use of resources for the benefit of the MS community. Member organizations include Accelerated Cure, Can Do Multiple Sclerosis, Consortium of Multiple Sclerosis Centers, International Organization of Multiple Sclerosis Nurses, Multiple Sclerosis Association of America, Multiple Sclerosis Foundation, National Multiple Sclerosis Society and United Spinal Association. MS Views and News serves as an affiliate member (since 2015).
- Treatment with a given disease-modifying medication should be continued indefinitely unless any of the following occur – in which case an alternative disease-modifying therapy should be considered:
  - Sub-optimal treatment response as determined by the individual and his or her treating clinician
  - Intolerable side effects, including significant laboratory abnormalities
  - Inadequate adherence to the treatment regimen
  - Availability of a more appropriate treatment option
  - The healthcare provider and patient determine that the benefits no longer outweigh the risks
- Movement from one disease-modifying therapy to another should occur only for medically appropriate reasons as determined by the treating clinician and patient.
- When evidence of additional clinical or MRI activity while on consistent treatment suggests a sub-optimal response, an alternative regimen (e.g., different mechanism of action) should be considered to optimize therapeutic benefit.
- The factors affecting choice of therapy at any point in the disease course are complex and most appropriately analyzed and addressed through a shared decision-making process between the individual and his or her treating clinician. Neither an arbitrary restriction of choice nor a mandatory escalation therapy approach is supported by data.

Access Considerations:
- Due to significant variability in the MS population, people with MS and their treating clinicians require access to the full range of treatment options for several reasons:
  - MS clinical phenotypes may respond differently to different disease-modifying therapies.
  - Different mechanisms of action allow for treatment change in the event of a sub-optimal response.
  - Potential contraindications limit options for some individuals.
  - Risk tolerance varies among people with MS and their treating clinicians.
  - Route of delivery, frequency of dosing and side effects may affect adherence and quality of life.
  - Individual differences related to tolerability and adherence may necessitate access to different medications within the same class.
  - Pregnancy and breastfeeding limit the available options.
- Individuals’ access to treatment should not be limited by their frequency of relapses, level of disability, or personal characteristics such as age, sex or ethnicity.
- Absence of relapses while on treatment is a characteristic of treatment effectiveness and should not be considered a justification for discontinuation of treatment.
- Treatment should not be withheld during determination of coverage by payers as this puts the patient at risk for recurrent disease activity.
Contents
ABSTRACT.................................................................................................................................................. 3
INTRODUCTION .............................................................................................................................................. 6
   Epidemiology, Demographics, Disease Course .......................................................................................... 6
   Inflammation and CNS Damage .............................................................................................................. 7
OVERVIEW OF FDA-APPROVED DISEASE-MODIFYING AGENTS IN MS ........................................... 9
DISEASE-MODIFYING THERAPY CONSIDERATIONS ........................................................................ 15
   Disease Factors Highlighting the Importance of Early Treatment ............................................................ 16
   Evidence Demonstrating the Impact of Treatment Following a First Clinical Event .................................. 18
   Evidence Demonstrating the Impact of Treatment on Relapsing MS ...................................................... 19
   Head-to-head comparison data in relapsing MS ....................................................................................... 26
   Evidence Demonstrating the Impact of Treatment on Progressive MS .................................................. 27
   Evidence Supporting the Need for Treatment to be Ongoing ................................................................. 29
   Use of Disease-Modifying Therapies in Pediatric MS ............................................................................ 30
   Treatment Considerations in Women and Men in Their Reproductive Years ........................................ 31
   Rationale for Access to the Full Range of Treatment Options ............................................................... 34
CONCLUSIONS REGARDING THE NEEDS OF PEOPLE WITH MS ........................................................ 39
   Treatment Considerations ....................................................................................................................... 39
   Access Considerations ........................................................................................................................... 40
REFERENCES ............................................................................................................................................... 41
APPENDICES ............................................................................................................................................... 60
   APPENDIX A: Multiple Sclerosis Disease Courses 2013 Revisions ....................................................... 60
   APPENDIX B: 2017 McDonald Criteria for the Diagnosis of Multiple Sclerosis ...................................... 64
   APPENDIX C: Treatments Used Off-Label for Multiple Sclerosis .......................................................... 65
THE MULTIPLE SCLEROSIS COALITION ................................................................................................. 72
INTRODUCTION
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS) characterized by inflammation, demyelination and degenerative changes. Most people with MS experience relapses and remissions of neurological symptoms, particularly early in the disease, and clinical events are usually associated with areas of CNS inflammation.\textsuperscript{1–4} Gradual worsening or progression, with or without subsequent acute attacks of inflammation or radiological activity, may be present very early, but usually becomes more prominent over time.\textsuperscript{5} While traditionally viewed as a disease solely of CNS white matter, more advanced imaging techniques have demonstrated significant early and ongoing CNS gray matter damage as well.\textsuperscript{6–9}

Those diagnosed with MS may have many fluctuating and disabling symptoms (including, but not limited to, fatigue, impaired mobility, mood and cognitive changes, pain and other sensory problems, visual disturbances and elimination dysfunction), resulting in a significant impact on quality of life for patients and their families. As the most common non-traumatic, disabling neurologic disorder of young adults – a group not typically faced with a chronic disease – MS threatens personal autonomy, independence, dignity and life planning,\textsuperscript{10} potentially limiting the achievement of life goals. The free-spirited spontaneity so highly valued by young adults needs to shift to purposeful planning, taking into account the challenges posed by fluctuations in function and an uncertain future. The patient’s self-definition, roles and relationships may be co-opted by the need to adapt to an unpredictable disease requiring frequent healthcare visits, periodic testing and costly medications.

Compared to patients with other chronic diseases, those diagnosed with MS have diminished ratings in health, vitality and physical functions, and experience limitations in social roles.\textsuperscript{11} Productivity and participation are affected for many, including early departure from the workforce and inability to fulfill household responsibilities.\textsuperscript{12} In a study of disease burden, based on data from the Medical Expenditure Panel Survey (MEPS) – a public access, large-scale database that links direct cost information with information on productivity and health-related quality of life – Campbell and colleagues found that annual direct healthcare costs for people with MS were $24,327 higher than for the general population. In addition, people with MS had a significantly higher risk of being unemployed, spent significantly more time in bed, and lost on average 10.04 quality-adjusted life years compared to the general population. In a systematic review of 48 cost-of-illness studies, medications were the main expense for those with milder disease while loss of income combined with informal care needs contributed the biggest costs for those with more advanced disease.\textsuperscript{13,14} Furthermore, registry studies specific to MS and large population cohort studies of individuals untreated with a disease-modifying therapy have demonstrated a reduced life expectancy of 8-12 years.\textsuperscript{15}

Epidemiology, Demographics, Disease Course
It is estimated that there are more than two million people with MS worldwide,\textsuperscript{16} with the number approaching 1,000,000 in the United States.\textsuperscript{17} Women are affected at least three times more than men\textsuperscript{18} and Caucasians are affected more than other racial groups.\textsuperscript{19} However, a recent study\textsuperscript{20} suggested that African American women have a higher than previously reported risk of developing MS and several studies have suggested that African Americans\textsuperscript{21–25} and Hispanics\textsuperscript{26–30} may have a more active, rapidly progressive disease course. MS is typically diagnosed in early adulthood, but the age range for disease onset is wide with both pediatric cases and new onset in older adults. Historically, a geographic gradient has been observed with a higher incidence of MS with increased distance from the equator.\textsuperscript{31,32} However, some recent studies have not demonstrated the same latitudinal gradient,\textsuperscript{33,34} suggesting either a change in regional risk determinants for MS or a broadening of the prevalence and recognition of MS worldwide.

The course of MS varies. However, 85-90 percent of individuals demonstrate a relapsing pattern at onset, which transitions over time in most untreated patients to a pattern of progressive worsening with few or no relapses or MRI activity (secondary progressive MS). Approximately 10-15 percent present with a relatively steady progression of symptoms over time (primary progressive MS), of which some will subsequently experience inflammatory activity by clinical or MRI criteria.\textsuperscript{1,2} This primary progressive course is generally diagnosed at an older age, is typically spinal cord-predominant, and is distributed more equally in men and women. The 2013 revisions to the MS clinical course descriptions\textsuperscript{1} further characterize relapsing and progressive MS as active (new relapses and/or new MRI activity) or not active, and worsening (disability
Prior to the era of disease-modifying treatments, approximately half of patients diagnosed with relapsing MS would progress to secondary progressive MS by 10 years, and 80-90 percent would do so by 25 years.\(^{35-37}\) Approximately half of patients would no longer be able to walk unaided by 15 years.\(^{36}\) More recent data in the era of disease-modifying therapy demonstrate that the percentage of patients with relapsing MS who develop secondary progressive MS may now be 15-30 percent.\(^{38}\)

**Inflammation and CNS Damage**

At present, much of the CNS damage in MS is believed to result from an immune-mediated process. Although the cause of the immunological changes is not completely understood, Vitamin-D deficiency, which is commonly present in MS, is thought to enhance inflammation. Gut dysbiosis is also thought to contribute to MS pathogenesis through mechanisms that have yet to be defined.\(^{39}\)

This immune-mediated process includes components of the innate immune system (including macrophages, natural killer cells and others) as well as adaptive immune system activation of certain lymphocyte populations in peripheral lymphoid organs.\(^{40}\) CD4+ lymphocytes, CD8+ lymphocytes and B lymphocytes are activated in the peripheral lymph tissues. Antigen presentation to naïve CD4+ lymphocytes causes differentiation into various T lymphocyte cell populations, depending on the antigen presented, the cytokine environment and the presence of co-stimulatory molecules. The T lymphocyte cell populations include Th1 and Th17 lymphocytes (which are associated with a variety of inflammatory cytokines that activate macrophages and opsonizing antibodies) and Th2 lymphocytes and T regulatory cells (which drive humoral immunity or secrete anti-inflammatory cytokines).\(^{40-42}\) In people with MS, there is a bias towards a Th1 and Th17 environment with T regulatory dysfunction that allows inflammation to predominate.\(^{43}\) Secreted cytokines and matrix metalloproteinases disrupt the blood-brain barrier.\(^{44}\) This disruption, along with up-regulation of adhesion molecules on blood vessel endothelium and activation of T cells, allows T cells to gain entry into the CNS, where additional activation takes place that initiates a damaging inflammatory cascade of events within the CNS. Multiple inflammatory cells become involved, including microglial cells and macrophages. In addition to CD4+ activation, CD8+ T lymphocytes have also been identified as important contributors to damaging CNS inflammation, and in fact have been identified by numerous researchers as the predominant T cell present in active MS lesions.\(^{45}\) Mechanisms of remission and recovery are not fully understood but are believed to be mediated by the expansion of regulatory cells that downregulate inflammation such as Foxp3 positive cells, Tr1 (IL-10 secreting), Th3 (TGF-B secreting) and CD56bright NK cells. Proliferation of progenitor oligodendroglia and remyelination contribute to recovery at least in the early stages of the disease.\(^{46}\)

Further contributions to CNS damage in MS are associated with B cell activation. B cells function as antigen presenting cells and also produce antibodies and pro-inflammatory cytokines that have damaging effects on myelin, oligodendrocytes and other neuronal structures.\(^{47}\) The importance of B cells in MS immunopathogenesis is supported by the consistent finding of oligoclonal immunoglobulins in the CSF; the successful clinical trials with B cell depleting monoclonal antibodies (rituximab and more recently ocrelizumab) that showed efficacy in RRMS and a subset of patients with primary progressive disease; and the presence of B-cell enriched meningeal follicles in progressive patients.\(^{48}\)

Recent studies have also revealed that mitochondrial damage, possibly as a result of free radical, reactive oxygen species and nitrous oxide (NO) activity associated with activated microglia, and iron deposition occur in MS, and make a significant contribution to demyelination and oligodendrocyte damage.\(^{49-51}\)

Immune-mediated responses leading to inflammation, with secretion of inflammatory cytokines, activation of microglia, T and B cell activity, mitochondrial damage and inadequate regulatory function, are believed to be at least partially responsible for demyelination, oligodendrocyte loss and axonal damage – all of which occur in acute inflammatory lesions.\(^{51,52}\) Axons that survive acute attacks may require increased energy to compensate for damage leading to later death from metabolic stress.\(^{51}\) Axonal loss, which correlates best with
disability, begins early in the disease process as evidenced by identified pathological changes as well as imaging studies.\textsuperscript{52,53}

Figure 1: Inflammatory cascade in multiple sclerosis

**Inflammatory Cascade in Multiple Sclerosis**

**Periphery**

1. Antigen presentation to CD4+ prompting activation and proliferation of pro-inflammatory lymphocytes (Th1 and Th17)

2. Secretion of pro-inflammatory cytokines

3. Up-regulation of adhesion molecules

4. T cell migration across the blood brain barrier into the CNS

5. B cell activation, proliferation and migration into the CNS

6. Migration of monocytes and macrophages into the CNS

7. Inadequate T regulatory function

**CNS**

8. Presentation of CNS antigen to T cell with reactivation

9. Recruitment of other inflammatory cells:
   - CD8+
   - B cells
   - monocytes
   - macrophages
   - microglia

10. Damage to myelin, oligodendrocytes and axons resulting from:
    - cytokine damage
    - antibody activity
    - complement damage
    - oxidative stress
    - mitochondrial dysfunction

**Blood Brain Barrier**
Currently, 17 disease-modifying agents are approved by the U.S. Food and Drug Administration (FDA).

Note: Zinbryta (daclizumab) was approved to treat relapsing forms of MS in 2016 and voluntarily withdrawn from the market in 2018.

Table 1: FDA-approved disease-modifying agents in MS (in alphabetical order by route of administration).

Refer to the full FDA prescribing information for each medication for contraindications and additional details about side effects, warnings and precautions, and pre-treatment recommendations and procedures.

FDA pregnancy categories were replaced by pregnancy guidelines in June 2015 to make them more meaningful for patients and providers, and to allow for patient-specific counseling and informed decision-making (see pages 31-34).

<table>
<thead>
<tr>
<th>Agent - Self-Injected</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>glatiramer acetate⁵⁴,⁵⁵ (Copaxone®, Glatopa®, therapeutic equivalent; Glatiramer acetate injection)</td>
<td>Mechanism of action in MS is not fully understood. Subsequent research suggests: - Promotes differentiation in Th2 and T-reg cells leading to bystander suppression in CNS.⁵⁶ - Increases release of neurotrophic factors from immune cells.⁵⁶ - Deletion of myelin-reactive T cells.⁵⁶</td>
<td>Injection-site reactions - Lipoatrophy - Vasodilation, rash, dyspnea - Chest pain - Lymphadenopathy⁵⁴</td>
<td>Immediate transient post-injection reaction (flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and/or urticaria) - Lipoatrophy and skin necrosis - Potential effects on immune response</td>
</tr>
<tr>
<td>interferon beta-1a⁵⁷ (Avonex®)</td>
<td>Mechanism of action in MS is unknown. Subsequent research suggests: - Promotes shift from Th1-Th2. - Reduces trafficking across Blood Brain Barrier (BBB).⁵⁸,⁵⁹ - Restores T-reg cells.⁵⁶ - Inhibits antigen presentation.⁵⁶ - Enhances apoptosis of autoreactive T-cells.⁵⁶</td>
<td>Flu-like symptoms - Depression - Elevated hepatic transaminases</td>
<td>Depression, suicide and/or psychosis - Hepatic injury - Anaphylaxis and other allergic reactions - CHF - Lower peripheral blood counts - Seizures - Other autoimmune disorders - Thrombotic microangiopathy</td>
</tr>
<tr>
<td>interferon beta-1a⁶⁰ (Rebi®, Extavia®)</td>
<td>Same as above</td>
<td>Injection-site reactions - Flu-like symptoms - Abdominal pain - Depression - Elevated hepatic transaminases - Hematologic abnormalities</td>
<td>Depression and/or suicide - Hepatic injury - Anaphylaxis and other allergic reactions - Injection-site reactions including necrosis - Lower peripheral blood counts - Seizures - Thrombotic microangiopathy</td>
</tr>
<tr>
<td>interferon beta-1b⁶¹,⁶² (Betaseron® (Extavia®)</td>
<td>Same as above</td>
<td>Flu-like symptoms - Injection-site reactions - Elevated hepatic transaminases - Low WBC - See warnings⁶¹,⁶²</td>
<td>Hepatic injury - Anaphylaxis and other allergic reactions - Depression and/or suicide - CHF - Injection-site necrosis - Low WBC - Flu-like symptoms - Seizures - Thrombotic microangiopathy</td>
</tr>
<tr>
<td>Agent - Self-Injected</td>
<td>Proposed MoA</td>
<td>Side Effects</td>
<td>Warnings/Precautions</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------------</td>
</tr>
</tbody>
</table>
| peginterferon beta-1a<sup>63-65</sup> (Plegridy®) | Same as above | - Flu-like symptoms  
- Injection-site reactions  
- Elevated hepatic transaminases  
- Low WBC  
- See warnings<sup>63</sup> | - Depression and/or suicide  
- Hepatic injury  
- Anaphylaxis and other allergic reactions  
- CHF  
- Low peripheral blood counts  
- Seizures  
- Other autoimmune disorders  
- Thrombotic microangiopathy |
| 125mcg SC every two weeks | Indication: relapsing forms of MS | |

<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
</table>
| cladribine<sup>66,67</sup> (Mavenclad®) | Mechanism has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis resulting in depletion of lymphocytes. | - Upper respiratory tract infection  
- Headache  
- Lymphopenia  
- Nausea  
- Back pain  
- Arthralgia and arthritis  
- Insomnia  
- Bronchitis  
- Hypertension  
- Fever  
- Depression | - Malignancies  
- Risk of teratogenicity  
- Lymphopenia  
- Infections (mostly frequent: herpes zoster, pyelonephritis)  
- Hematologic toxicity  
- Graft-vs-host disease with blood transfusion; irradiation of cellular blood products prior to administration is recommended in the event of transfusion  
- Liver Injury  
- Hypersensitivity  
- Cardiac failure  
- Screen for: hepatitis B and C, VZV, tuberculosis, HIV  
- Baseline (within three months) MRI before initiating first treatment course; at first sign or symptom of PML, withhold medication  
- Administer all immunizations according to immunization guidelines prior to starting treatment; administer live-attenuated or live vaccines at least 4-6 weeks prior to starting treatment; Avoid live-attenuated or live vaccines during or after treatment until white blood cell counts are within normal limits  
- Boxed Warning  
Malignancies and risk of teratogenicity  
- Anaphylaxis and angioedema  
- PML  
- Lymphopenia (consider discontinuing treatment in patients with persistent lymphopenia (<500) lasting over six months)  
- Flushing  
- Liver injury |
| Recommended cumulative dosage - 3.5 mg/kg body weight administered orally and divided into two yearly treatment courses (1.75 mg/kg per treatment course); each treatment course divided into two treatment cycles separated by 23-27 days (see PI). | |
| Indication: relapsing forms of MS, including relapsing-remitting and active secondary progressive disease. Use is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug. Use is not recommended for patients with CIS because of its safety profile. | |

| dimethyl fumarate<sup>68</sup> (Tecfidera®) | Mechanism of action in MS is unknown. It has been shown to promote anti-inflammatory and cytoprotective activities mediated by Nrf2 pathway.<sup>59</sup> | - Anaphylaxis and angioedema  
- Progressive multifocal leukoencephalopathy (PML)  
- Lymphopenia  
- Elevated AST  
- Flushing  
- GI symptoms  
- Pruritis  
- Rash<sup>65</sup> | - Anaphylaxis and angioedema  
- PML  
- Lymphopenia (consider discontinuing treatment in patients with persistent lymphopenia (<500) lasting over six months)  
- Flushing  
- Liver injury |
| 240mg PO twice daily | Indication: relapsing forms of MS | |


**Agent – Oral**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
</table>
| fingolimod<sup>69</sup> (Gilenya<sup>®</sup>) | Mechanism of action in MS most likely involves blocking of S1P receptor on lymphocytes thus preventing their egress from secondary lymph organs.<sup>69</sup> | - Headache  
- Influenza  
- Diarrhea  
- Back pain  
- Elevated hepatic enzymes  
- Cough  
- Bradycardia following first dose  
- Macular edema  
- Lymphopenia  
- Bronchitis/pneumonia | - Bradyarrhythmia and/or atrioventricular block following first dose  
- Risk of infections including serious infections – monitor for infection during treatment and for two months after d/c  
- Patients without confirmed history of chickenpox or without documented full course of vaccination against VZV should be tested for antibodies before treatment; vaccination of antibody-negative patients is recommended, with 1-month delay before treatment initiation  
- PML  
- Cryptococcal infections  
- Macular edema  
- Posterior reversible encephalopathy syndrome (PRES)  
- Low pulmonary function tests (<Sup>FEV</Sup>)  
- Hepatic injury  
- Increased BP  
- Basal cell carcinoma  
- Fetal risk: women should avoid conception for two months after treatment d/c  
- Decreased lymphocyte counts for two months after drug d/c  
- Severe increase in disability after stopping treatment  
Avoid live attenuated vaccines during treatment and for two months after d/c |
<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
</table>
| siponimod⁷⁰,⁷¹ (Mazen®) | And sphingosine-1-phosphate (S1P) receptor modulator that blocks lymphocyte egress from lymph nodes | - Headache  
- Hypertension  
- ↑Transaminase  
- Falls  
- Peripheral edema  
- Nausea  
- Dizziness  
- Diarrhea  
- Bradycardia | - Infections; CBC monitoring before and during treatment; do not start treatment in patients with active infection  
- Macular edema: ophthalmic evaluation recommended before starting treatment and if there is any change in vision while on treatment; diabetes mellitus and uveitis increase the risk  
- Test patients for antibodies to VZV before treatment; VZV vaccination of antibody-negative patients is recommended prior to treatment  
- Bradyarrhythmia and atrioventricular conduction delays: treatment may result in a transient decrease in heart rate; titration is required for treatment initiation; consider resting heart rate with concomitant betablocker use; obtain cardiologist consultation before concomitant use with other drugs that decrease heart rate  
- Respiratory effects: may cause a decline in pulmonary function; assess pulmonary function (e.g., spirometry) if clinically indicated  
- Liver injury: obtain liver enzyme results before initiation; closely monitor patients with severe hepatic impairment; discontinue if significant liver injury occurs  
- ↑BP: monitor BP during treatment  
- Fetal risk: women of childbearing potential should use effective contraception during and for 10 days after d/c  
- Posterior reversible encephalopathy syndrome (PRES)  
- Potential unintended additive immunosuppressive effect when switching from other immunosuppressive or immune-modulating therapies; initiating siponimod after treatment with alemtuzumab is not recommended  
- Use caution regarding the concomitant use of other drugs that are CYP2C9 and CYP23A4 inhibitors or inducers  
- Severe exacerbation of disease, including disease rebound, is possible following d/c  
- Siponimod remains in the blood for up to 10 days following d/c |

- Assessments (CYP2C9 genotype determination, CBC, ophthalmic, cardiac) required prior to initiating treatment  
- Titration required for treatment initiation  
- Recommended maintenance dosage - 2 mg  
- Recommended maintenance dosage in patients with a CYP2C9*1/*3 or *2/*3 genotype - 1 mg  
- First-dose monitoring is recommended for patients with sinus bradycardia, first- or second-degree [Mobitz type I] atrioventricular (AV) block, or a history of myocardial infarction or heart failure  

Indication: for the treatment of adults with relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease
<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>teriflunomide(^{72}) (Aubagio®)</td>
<td>Mechanism of action in MS is unknown.(^{72,73}) It has been shown to: - Have a cytostatic effect on rapidly dividing T- and B-lymphocytes in the periphery. - Inhibit de novo pyrimidine synthesis. It is a metabolite of leflunomide (used in rheumatoid arthritis (RA)).</td>
<td>- ALT elevation - Alopecia - Diarrhea - Influenza - Nausea - Paresthesia(^{72})</td>
<td>- Hepatotoxicity - Risk of teratogenicity - Elimination of teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days (confirm undetectable drug level before conception) - Decreased neutrophils, lymphocytes and platelets - Risk of infection, including tuberculosis (TB screen prior to treatment) - Potential increased risk of malignancy - Peripheral neuropathy (consider discontinuation of treatment) - Acute renal failure - Treatment-emergent hyperkalemia - Increased renal uric acid clearance - Interstitial lung disease - Stevens-Johnson syndrome and toxic epidermal necrolysis (stop treatment) - Increased BP - May decrease WBC; recent CBC prior to initiation; monitor for infections; consider suspension for serious infections; do not start in presence of infection - Concomitant use with immunosuppressants has not been evaluated - No live virus vaccines Note: Some of these were carried over from leflunomide use in RA</td>
</tr>
<tr>
<td>alemtuzumab(^{74-76}) (Lemtrada®)</td>
<td>Mechanism of action in MS is presumed to involve binding to CD52, a cell surface molecule present on T and B lymphocytes, and on natural killer cells, monocytes and macrophages. This results in antibody-dependent cellular cytolysis and complement-mediated lysis.(^{74,77})</td>
<td>- More than 90% of patients in clinical trials experienced infusion reactions: skin rash, fever, headache, muscle aches and/or temporary reoccurrence of previous neurologic symptoms. More serious but uncommon infusion reactions include anaphylaxis and/or heart rhythm abnormalities. - Serious adverse reactions include autoimmunity, infusion reactions, malignancies, immune thrombocytopenia (ITP), glomerular nephropathies and/or other cytopenias) - Infections - Malignancies (thyroid, melanoma or lymphoproliferative) - Pneumonitis - Stroke, cervicocephalic arterial dissection - No live virus vaccinations following infusion</td>
<td>- Infusion reactions - Autoimmunity (thyroid disorders, immune thrombocytopenia (ITP), glomerular nephropathies and/or other cytopenias) - Infections - Malignancies (thyroid, melanoma or lymphoproliferative) - Pneumonitis - Stroke, cervicocephalic arterial dissection - No live virus vaccinations following infusion <strong>Boxed Warning</strong> Because of the risk of autoimmunity, life threatening infusion reactions and malignancies, alemtuzumab is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) program.</td>
</tr>
</tbody>
</table>

---

**Agent – Oral**

- **teriflunomide**\(^{72}\) (Aubagio®)
  - 7mg or 14mg PO daily
  - Indication: relapsing forms of MS

**Proposed MoA**

- Mechanism of action in MS is unknown.\(^{72,73}\) It has been shown to:
  - Have a cytostatic effect on rapidly dividing T- and B-lymphocytes in the periphery.
  - Inhibit de novo pyrimidine synthesis.
  - It is a metabolite of leflunomide (used in rheumatoid arthritis (RA)).

**Side Effects**

- ALT elevation
- Alopecia
- Diarrhea
- Influenza
- Nausea
- Paresthesia\(^{72}\)

**Warnings/Precautions**

- Hepatotoxicity
- Risk of teratogenicity
- Elimination of teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days (confirm undetectable drug level before conception)
- Decreased neutrophils, lymphocytes and platelets
- Risk of infection, including tuberculosis (TB screen prior to treatment)
- Potential increased risk of malignancy
- Peripheral neuropathy (consider discontinuation of treatment)
- Acute renal failure
- Treatment-emergent hyperkalemia
- Increased renal uric acid clearance
- Interstitial lung disease
- Stevens-Johnson syndrome and toxic epidermal necrolysis (stop treatment)
- Increased BP
- May decrease WBC; recent CBC prior to initiation; monitor for infections; consider suspension for serious infections; do not start in presence of infection
- Concomitant use with immunosuppressants has not been evaluated
- No live virus vaccines

**Boxed Warning**

- Hepatotoxicity and risk of teratogenicity

---

**Agent - Intravenous**

- **alemtuzumab**\(^{74-76}\) (Lemtrada®)
  - 12mg/day IV on five consecutive days followed 12 months later by 12mg/day on three consecutive days
  - Indication: relapsing forms of MS – Generally for patients who have had an inadequate response to two or more MS therapies

**Proposed MoA**

- Mechanism of action in MS is presumed to involve binding to CD52, a cell surface molecule present on T and B lymphocytes, and on natural killer cells, monocytes and macrophages. This results in antibody-dependent cellular cytolysis and complement-mediated lysis.\(^{74,77}\)

**Side Effects**

- More than 90% of patients in clinical trials experienced infusion reactions: skin rash, fever, headache, muscle aches and/or temporary reoccurrence of previous neurologic symptoms. More serious but uncommon infusion reactions include anaphylaxis and/or heart rhythm abnormalities.
- Serious adverse reactions include autoimmunity, infusion reactions, malignancies, immune thrombocytopenia (ITP), glomerular nephropathies and/or other cytopenias.

**Warnings/Precautions**

- Infusion reactions
- Autoimmunity (thyroid disorders, immune thrombocytopenia (ITP), glomerular nephropathies and/or other cytopenias)
- Infections
- Malignancies (thyroid, melanoma or lymphoproliferative)
- Pneumonitis
- Stroke, cervicocephalic arterial dissection
- No live virus vaccinations following infusion

**Boxed Warning**

- Because of the risk of autoimmunity, life threatening infusion reactions and malignancies, alemtuzumab is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) program.
<table>
<thead>
<tr>
<th>Agent - Intravenous</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
</table>
| **alemtuzumab (continued)** | - Disrupts DNA synthesis and repair  
- Inhibits B cell, T cell, and macrophage proliferation  
- Impairs antigen presentation  
- Impairs secretion of interferon gamma, TNFα and IL-2 | - Immediate and significant depletion of lymphocytes; herpes simplex and zoster infections more common in patients who received alemtuzumab in the clinical trials, especially soon after the infusions. Prophylaxis with anti-viral agent is recommended for at least two months or until CD4 count is >200. | - Severe local tissue damage if there is extravasation  
- Cardiotoxicity  
- Acute myelogenous leukemia  
- Myelosuppression  
**Boxed Warning**  
MS patients:  
- with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone  
- should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose  
- should undergo quantitative re-evaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF; additional doses of mitoxantrone should not be administered to multiple sclerosis patients who have had either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy  
- should not receive a cumulative mitoxantrone dose greater than 140 mg/m²  
- should undergo yearly quantitative LVEF evaluation after stopping Mitoxantrone to monitor for late occurring cardiotoxicity  
Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia. |
| **mitoxantrone**<sup>78</sup>  
*(Novantrone®)* | - 12mg/m² IV every three months; maximum cumulative dose: 140mg/m²  
Indication: worsening relapsing-remitting, progressive-relapsing or secondary progressive MS | - Temporary blue discoloration of sclera and urine  
- Nausea  
- Alopecia  
- Menstrual disorders including amenorrhea and infertility  
- Infections (URI, UTI, stomatitis)  
- Cardiac toxicity (arrhythmia, abnormal EKG and/or congestive heart failure)  
- Severe local tissue damage if there is extravasation | - **Boxed Warning**  
MS patients:  
- with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone  
- should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose  
- should undergo quantitative re-evaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF; additional doses of mitoxantrone should not be administered to multiple sclerosis patients who have had either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy  
- should not receive a cumulative mitoxantrone dose greater than 140 mg/m²  
- should undergo yearly quantitative LVEF evaluation after stopping Mitoxantrone to monitor for late occurring cardiotoxicity  
Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia. |
| **natalizumab**<sup>79</sup>  
*(Tysabri®)* | - The mechanism of action in MS has not been fully defined. It has been shown to:  
- Block α4-integrin on lymphocytes, thus reducing trafficking of lymphocytes into the CNS,<sup>59</sup>  
- Disrupts DNA synthesis and repair  
- Inhibits B cell, T cell, and macrophage proliferation  
- Impairs antigen presentation  
- Impairs secretion of interferon gamma, TNFα and IL-2 | - Headache  
- Fatigue  
- Urinary tract infection  
- Lower respiratory tract infection  
- Arthralgia  
- Urticaria  
- Gastroenteritis  
- Vaginitis  
- Depression  
- Diarrhea<sup>79</sup>  
- PML  
- Hepatotoxicity  
- Herpes encephalitis and meningitis caused by herpes simplex and varicella zoster viruses  
- Acute retinal necrosis  
- Hypersensitivities  
- Immunosuppression/infections  
**Boxed Warning**  
Because of the risk of PML, natalizumab is available only through |

<sup>78</sup>Indication: worsening relapsing-remitting, progressive-relapsing or secondary progressive MS  
<sup>79</sup>Indication: relapsing forms of MS  
<sup>59</sup>The mechanism of action in MS has not been fully defined. It has been shown to:  
- Block α4-integrin on lymphocytes, thus reducing trafficking of lymphocytes into the CNS,
DISEASE-MODIFYING THERAPY CONSIDERATIONS

Several important themes emerge from the growing body of evidence in MS therapeutics:

1) Early successful control of disease activity – including the reduction of clinical and sub-clinical attacks and the delay of the progressive phase of the disease – appears to play a key role in preventing accumulation of disability, prolonging the ability of people with MS to remain active and engaged, and protecting quality of life.

2) Physical impairments comprise only one aspect of disability that results from early disease activity and disease progression. Cognitive impairment and fatigue are common early in the disease process and cause disability independent of physical function. In addition, common physical comorbidities in MS are associated with persistent fatigue, and depression at baseline is associated with worsening fatigue over time.

3) Prognosis at the individual level remains highly variable and unpredictable.

4) Adherence to treatment is important to efficacy and may be impacted by a wide range of factors requiring early identification and intervention.

In 2018, the American Academy of Neurology published the Practice Guideline: Disease-Modifying Therapies for Adults with Multiple Sclerosis. The Guideline provides evidence-based recommendations for starting, switching and stopping disease-modifying agents. These recommendations consider the patient’s perspective in the complex decision-making process in order to enhance shared decision-making. Refer to the full Guideline at AAN.com/guidelines. In the same year, ECTRIMS and the EAN (European Academy of Neurology) published the ECTRIMS/EAN Guideline on the Pharmacological Treatment of People with Multiple Sclerosis. Refer to this guideline for additional expert recommendations for the adult MS population.

---

### DISEASE-MODIFYING AGENTS

<table>
<thead>
<tr>
<th>Agent - Intravenous</th>
<th>Proposed MoA</th>
<th>Side Effects</th>
<th>Warnings/Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>natalizumab (continued)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ocrelizumab&lt;sup&gt;80&lt;/sup&gt; (Ocrevus®)</td>
<td>600mg IV every 6 months</td>
<td><strong>Indication:</strong> relapsing or primary progressive forms of MS</td>
<td>- Infusion reactions (potentially life-threatening) - Infections - Possible increased risk of malignancies (including breast cancer, which occurred in 6 of 781 treated patients and no placebo patients) - Infusion reactions that can include: pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia. Premedication and observation period recommended. - Infections, including respiratory tract infections, herpes and potentially PML - Hepatitis B reactivation - Possible increased immunosuppressive effect if immunosuppressant used prior to or after ocrelizumab - Malignancies - Administer all vaccinations at least 6 weeks prior to administration of ocrelizumab; no live-attenuated or live vaccines during treatment and until B-cell repletion.</td>
</tr>
</tbody>
</table>

Disease Factors Highlighting the Importance of Early Treatment

The goal of disease-modifying treatment is to reduce the early clinical and sub-clinical disease activity that is thought to contribute to long-term disability. 84,85

The following points highlight the importance of early treatment:

- **Neuroinflammation and neurodegeneration occur simultaneously throughout the disease course**

  It had long been thought that MS was characterized by early inflammatory damage followed by later neurodegeneration. However, a growing body of evidence demonstrates that inflammation and degeneration occur simultaneously, that clinical recovery reflects reserve capacity, and that subclinical damage ultimately leads to permanent clinical deficits. Evidence also indicates that inflammation contributes to worsening progression, even if not the sole cause. Hence, inflammation and degeneration are inter-related rather than independent. 86,87 Additional evidence to support neuroinflammatory and neurodegenerative changes throughout the disease process includes:

  - Early in MS, new MRI activity, evidenced by gadolinium enhancement, occurs approximately 7-10 times more frequently than clinical activity. 88
  - Early in the disease process, advanced MRI techniques demonstrate abnormalities in normal appearing white matter as well as gray matter in the absence of focal lesions seen on conventional imaging. 7
  - Brain atrophy has been identified in early MS, even at the time of the first clinical attack. 89
  - Atrophy has been seen in radiologically isolated syndrome (RIS – the incidental finding of MS-like lesions in the absence of known clinical relapses) 90,91
  - Inflammatory activity has been observed in patients with both relapsing and progressive forms of the disease. 3

  Given the evidence that inflammation and neurodegeneration are interrelated and occur throughout the disease process, prompt initiation and optimization of treatment help to minimize early inflammation and axonal damage.

- **Individuals with a first clinical event accompanied by MRI findings consistent with MS have a high probability of experiencing further clinical disease activity**

  The term “clinically-isolated syndrome” (CIS) has been used to describe a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation and demyelination in one or more sites in the CNS.

  Eighty percent of the placebo-treated patients in the four published phase III CIS trials with injectable medications had subsequent clinical events, which was defined at the time as conversion to clinically-definite MS (CDMS). 92–95 Follow-up data for these patients indicated a variable disease course, with approximately one-third having minimal clinical relapses and physical disability after 15-20 years, but 42-50 percent converting to secondary progressive (SPMS) with increasing disability. 96,97 Furthermore, baseline MRI findings in CIS predicted the development of definite MS as defined at the time. Lesion volume and the rate of lesion development earlier in the disease course were found to correlate with disability after 20 years. 97

  The importance of delaying and limiting additional relapses early in the disease process was further supported by a CIS trial with teriflunomide published in 2014.

  The 2017 revision of the McDonald diagnostic criteria (See Appendix B) facilitated an earlier diagnosis of MS based on a first clinical event, and MRI findings demonstrating dissemination in space and time. 99 Using these newer criteria, many individuals in the early CIS trials would already have been diagnosed with MS. Although the term “CIS” may be nearly obsolete today, the importance of delaying and limiting additional relapses early in the disease process remains clear.
Based on data from the published CIS trials, prompt identification of early relapsing patients with little or no disability is essential in order to achieve the best possible short- and long-term outcomes.85

- **Individuals with RIS are at significant risk for subsequent clinical disease activity**

Although RIS is not currently recognized as a separate MS phenotype (see Appendix A), emerging data100,101 suggest that within five years, 30 percent of patients with an RIS presentation develop a symptomatic clinical event and two-thirds demonstrate new lesions on MRI.90,102–104 In these studies, younger individuals with RIS and spinal cord lesions, CSF inflammatory markers, abnormal visual evoked potentials, and/or contrast enhancing MRI lesions were more likely to have a subsequent symptomatic CNS demyelinating event. Notably, nearly 10 percent of people with RIS were found to have a progressive course, thereby fulfilling criteria for PPMS.90,105 And, 20–30 percent of RIS patients demonstrate cognitive changes similar to those seen in patients with RRMS.106–108 In their review of these data, Lebrun and colleagues100 as well as Labiano-Fontcuberta and Benito-Leon101 recommended further study of RIS before a general recommendation for treatment can be made.

- **Early disease activity and disease course appear to impact long-term disability**

Debate is ongoing about the ways and extent to which early disease activity impacts long-term disability.

- Some evidence suggests that early disability progression as measured by the Expanded Disability Status Scale (EDSS)108 is the result of residual impairments from partially-resolved relapses.84,110–112 Natural history studies suggest that relapses in the first two years of disease impact early progression,113 with the impact of early relapses diminishing later in the disease course.114 However, Jokubaitis and colleagues found the effect of relapses on disability accrual in a treated cohort of patients to be significant, even for relapses that occurred ≥14 years after disease onset, although earlier relapses had the greatest impact.115

- The onset and evolution of secondary progressive MS (SPMS) – in which inflammatory attacks decrease – also appear to have an important association with long-term disability.116 From this perspective, earlier SPMS onset is a primary predictor of disability, which means that a person’s prognosis is essentially determined before progressive symptoms become predominant.

- Data from both early and late in the disease course highlight the impact of early disease activity on long-term outcomes. In patients identified as having CIS, Brex and colleagues117 found that increases in lesion volume on MRI in the first five years of the disease correlate with the degree of long-term disability. Data from the 16-year follow-up cohort study of the pivotal trial of interferon beta-1b suggest that long-term physical and cognitive outcomes may be determined early in the disease.118

Given the medications that are currently available – all of which primarily target inflammation – the optimal window for impacting long-term disability is during the early relapsing phase of the disease, with the goal being to slow the accumulation of lesion volume, decrease the number of relapses, and prevent disability from both unresolved relapses and disease progression.84

- **Cognitive changes, depression and fatigue occur very early in the disease process**

It is currently recognized that approximately 60–65 percent of people with MS will experience cognitive impairment;119 36–54 percent will experience a major depressive disorder;120 and up to 92 percent will experience significant fatigue,121 contributing to increased disability and reduction in quality of life.

- Evidence is accumulating that approximately 20–30 percent of people with a first clinical event have already experienced cognitive changes.122–128 In fact, cognitive deficits similar to those seen in RRMS have been found in 20–30 percent of individuals with RIS.106–108

- Some studies suggest that cognitive deficits may precede the onset of MS by as much as 1.2 years.122 More specifically, verbal deficits have been shown to occur early and may predict the presence of cognitive impairment in people with a first clinical event.124
- Early cognitive changes are also known to progress, even in people with little or no physical changes, and deterioration can be expected over a three-year period in approximately one-third of people with short disease duration.
- Cognitive deficits are detected in approximately 30 percent of pediatric MS patients.
- Depression and fatigue have been found along with cognitive deficits in early MS, with each having a significant impact on quality of life, employment and other important activities of daily life – findings that highlight the importance of early treatment to help preserve people’s ability to remain optimally engaged in everyday activities, including employment and social interactions.

- **So-called “benign MS” may not be benign for many people**

  The most common working definition of “benign MS” – an Expanded Disability Status Score (EDSS) $\leq 3$ at 10 years – is highly weighted for patients’ motor abilities and fails to capture non-motor components of the disease, particularly mood, cognition and fatigue.

  - In one cohort of individuals meeting the criteria for “benign MS,” 45 percent were found to be cognitively impaired, 49 percent had significant fatigue, and 54 percent were found to be depressed.
  - In another cohort of people with “benign MS” followed for 10.9 additional years, 81 percent (35/43) developed higher EDSS scores, cognitive impairment, pain and/or depression, as well as a significant increase in new or enlarging T2 lesions and gadolinium (Gd)-enhancing lesions over time.
  - Sayao and colleagues evaluated disease status in a “benign MS” cohort after 20 years and found that while 51 percent remained benign, 21 percent had progressed to EDSS $\geq 6$ and 23 percent had converted to SPMS. The authors concluded that appropriate criteria for determining which individuals will have a truly benign course of the disease have not yet been identified.

  Based on these findings, benign MS can only be diagnosed retrospectively, after a minimum of 20 years. Therefore, the term should only be applied – if at all – in retrospect, and any decision to delay treatment for a given individual needs to take into account non-motor as well as motor variables.

**Evidence Demonstrating the Impact of Treatment Following a First Clinical Event**

Although none of the available treatments are fully effective in stopping MS disease activity or disease progression, evidence points to the favorable impact of treatment following a first clinical event:

**Delaying conversion to clinically definite MS (CDMS)**

Each of four published placebo-controlled phase III trials of injectable medications in patients with clinically-isolated syndrome (CIS), as well as the CIS trial with teriflunomide, demonstrated that early treatment successfully delayed conversion to CDMS (as defined at the time of these trials) by 37–45 percent at two to three years compared with placebo.

The eight-year, open-label follow-up of the early intervention study with interferon beta-1b, which compared the immediate treatment group with the delayed treatment (placebo) group, further demonstrated a reduced risk of CDMS and longer median time to CDMS in the early treatment group, although the greatest differences occurred in the first year of treatment. A follow-up open-label phase of the early intervention study with glatiramer acetate demonstrated a reduced risk of CDMS and a delay in conversion to CDMS in the immediate treatment group as compared with the delayed treatment (placebo) group.

**Reducing brain atrophy and disability worsening**

In meta-analyses of CIS treatment trials, each of two years duration (ETOMS, PreCISe, TOPIC), the rate of brain atrophy was attenuated after one year of treatment.

In a large cohort of CIS patients, disease-modifying treatments reduced 3-month confirmed and 12-month sustained disability worsening.
Evidence Demonstrating the Impact of Treatment on Relapsing MS

Each of the approved disease-modifying therapies has been shown to provide significant benefits in relapsing forms of MS. *Due to differences in patient cohorts, trial designs and outcome measures, as well as changes in diagnostic criteria, these data should not be used to compare efficacy between specific agents except where they are compared in the same trial.*

Impact on clinical outcomes (relapse rates and disability progression)

Table 2: Disease-modifying therapies: pivotal trial data on relapse rate and disability progression (in alphabetical order within route of administration).*Primary outcomes are identified with a +.

<table>
<thead>
<tr>
<th>Agent - Self-Injected</th>
<th>Effect on Relapse Rate Compared to Placebo or Active Comparator*</th>
<th>Effect on Disability Progression Compared to Placebo or Active Comparator</th>
</tr>
</thead>
</table>
| glatiramer acetate145^  
20mg qd  
40mg tiw146 | 29% reduction in relapse rate over 24 months+: 1.68 placebo; 1.19 treated (p=0.007)  
34% reduction in annualized relapse rate at 12 months+: 0.505 placebo; 0.331 treated (p<0.0001) | Progression free at 24 months: 75.4% placebo; 78.4% treated (N.S.) |
| interferon beta-1a subcutaneous147 | 33.2% reduction (44mcg tiw vs. placebo)  
Mean number of relapses per person (24 months)+: 2.56 placebo; 1.73 treated (p=0.005) | 30% decrease in proportion of patients with sustained disability progression at 12 weeks+: 11.9 months placebo; 21.3 months treated (p=0.05) |
| interferon beta-1a intramuscular148 | 18% reduction^9  
Mean number of relapses per patient year: 0.82 placebo; 0.67 treated (p=0.04) | 37% decrease in time to disability progression sustained for at least six months+: 34.9% placebo; 21.9% treated (p=0.04) |
| interferon beta-1b149 | 34% reduction annualized relapse rate over two years+: 1.31 placebo; 0.9 treated (p=0.0001) | 29% decrease (N.S.) in significant change from baseline EDSS: 28% placebo; 20% treated |
| peginterferon beta-1a^64,65 | 36% reduction annualized relapse rate at 48 weeks+: 0.397 placebo; 0.256 treated (p=0.0007)^64  
Proportion of exacerbation-free patients+: 16% placebo; 25% treated (N.S.)^64  
Efficacy maintained beyond one year with dosing every two weeks providing greater efficacy than every four weeks^65 | 38% relative risk reduction in disability progression at 48 weeks: 10.5% placebo; 6.8% treated (p=0.0383)^64 |

* Comparison across clinical trials is impossible due to differences in patient populations, diagnostic definitions, primary and secondary endpoints and outcome metrics.
<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th><strong>Effect on Relapse Rate Compared to Placebo or Active Comparator</strong></th>
<th><strong>Effect on Disability Progression Compared to Placebo or Active Comparator</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>cladribine&lt;sup&gt;67&lt;/sup&gt;</td>
<td>58% decrease in annualized relapse rate at 96 weeks&lt;sup&gt;*&lt;/sup&gt;: 0.33% placebo; 0.14 treated (3.5 mg group) (p&lt;0.001)&lt;sup&gt;67&lt;/sup&gt;</td>
<td>33% decrease in relative risk of disability progression at three months HR 0.67 treated (3.5 mg group) (p=0.02)&lt;sup&gt;67&lt;/sup&gt;</td>
</tr>
<tr>
<td>dimethyl fumarate&lt;sup&gt;150,151&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 49% reduction in proportion relapsing within two years&lt;sup&gt;<em>&lt;/sup&gt;: 46% placebo; 27% treated (p&lt;0.001)&lt;sup&gt;150&lt;/sup&gt;  <strong>Study 2:</strong> 44% reduction in annualized relapse rate at two years&lt;sup&gt;</em>&lt;/sup&gt;: 40% placebo; 22% DMF bid (p&lt;0.001)&lt;sup&gt;151&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 38% decrease in risk of disability progression at 12 weeks&lt;sup&gt;64,50&lt;/sup&gt;; 27% placebo; 16% treated (p=0.005)&lt;sup&gt;150&lt;/sup&gt;  <strong>Study 2:</strong> Estimated proportion of patients with progression at 2 years: 17% placebo; 13% DMF bid (N.S.)&lt;sup&gt;151&lt;/sup&gt;</td>
</tr>
<tr>
<td>fingolimod&lt;sup&gt;152,153&lt;/sup&gt; <em>(compared to IFN beta-1a in Study 3)</em>&lt;sup&gt;154&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 54% reduction in annualized relapse rate over two years&lt;sup&gt;<em>&lt;/sup&gt;: 0.40 placebo; 0.18 0.5mg dose (p&lt;0.001)&lt;sup&gt;152&lt;/sup&gt;  <strong>Study 2:</strong> 48% reduction in annualized relapse rate over two years&lt;sup&gt;</em>&lt;/sup&gt;: 0.40 placebo; 0.21 0.5mg dose (p&lt;0.0001)&lt;sup&gt;153&lt;/sup&gt;  <strong>Study 3:</strong> Annualized relapse rate over 12 months&lt;sup&gt;*&lt;/sup&gt;: 0.33 IFN; 0.16 0.5mg dose (p&lt;0.001)&lt;sup&gt;154&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 30% decrease in risk of disability progression (p=0.03 0.5mg dose)&lt;sup&gt;152&lt;/sup&gt; Percent with absence of disability progression at three months: 75.9% placebo; 82.3% 0.5mg dose (p=0.03)&lt;sup&gt;152&lt;/sup&gt;  <strong>Study 2:</strong> Percent with absence of disability progression at three months: 71.0% placebo; 74.7% 0.5mg dose (N.S.)&lt;sup&gt;153&lt;/sup&gt;  <strong>Study 3:</strong> Percent with absence of disability progression at three months: 92.1% IFN; 94.1% 0.5mg dose (p=0.25)&lt;sup&gt;154&lt;/sup&gt;</td>
</tr>
<tr>
<td>siponimod&lt;sup&gt;71&lt;/sup&gt;</td>
<td>Annualized relapse rate (defined as average number of confirmed relapses per year): 55% relative reduction: 0.16 placebo; 0.07 treated (p&lt;0.01)&lt;sup&gt;71&lt;/sup&gt;</td>
<td>Confirmed disability progression at three months: 32% placebo; 26% treated, HR 0.79 (p=0.013)</td>
</tr>
<tr>
<td>teriflunomide&lt;sup&gt;155,156&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 31% reduction in annualized relapse rate over two years&lt;sup&gt;<em>&lt;/sup&gt;: 0.54 placebo; 0.37 for 7mg and 14mg doses (p&lt;0.001)&lt;sup&gt;155&lt;/sup&gt;  <strong>Study 2:</strong> Annualized relapse rate over two years&lt;sup&gt;</em>&lt;/sup&gt;: 0.50 placebo; 0.39 for 7mg dose (p&lt;0.0183) and 0.32 for 14 mg dose (p&lt;0.0001)&lt;sup&gt;156&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> Proportion with confirmed disability progression at 12 weeks: 27.3% placebo; 21.7% 7mg dose (N.S.); 20.2% 14mg dose (p=0.03)&lt;sup&gt;155&lt;/sup&gt;  <strong>Study 2:</strong> Risk of sustained accumulation of disability compared to placebo: 7mg dose (N.S.); 31.5% 14mg dose (p=0.04)&lt;sup&gt;156&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agent – Intravenous</th>
<th><strong>Effect on Relapse Rate Compared to Placebo or Active Comparator</strong></th>
<th><strong>Effect on Disability Progression Compared to Placebo or Active Comparator</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>alemtuzumab&lt;sup&gt;75,76&lt;/sup&gt; <em>(compared to IFN beta-1a 44mcg tiw)</em></td>
<td><strong>Study 1:</strong> 55% reduction in annualized relapse rate over two years&lt;sup&gt;<em>&lt;/sup&gt;: 0.39 IFN; 0.18 alemtuzumab (p&lt;0.0001)&lt;sup&gt;75&lt;/sup&gt;  <strong>Study 2:</strong> 49% reduction in annualized relapse rate over two years&lt;sup&gt;</em>&lt;/sup&gt;: 0.52 IFN; 0.26 alemtuzumab (p&lt;0.0001)&lt;sup&gt;76&lt;/sup&gt;</td>
<td><strong>Study 1:</strong> 30% relative risk reduction at year two sustained disability accumulation confirmed over six months&lt;sup&gt;<em>&lt;/sup&gt;: 11% IFN; 8% alemtuzumab (N.S.)&lt;sup&gt;75&lt;/sup&gt;  <strong>Study 2:</strong> 42% relative risk reduction at year 2 sustained disability accumulation confirmed over six months&lt;sup&gt;</em>&lt;/sup&gt;: 20% IFN; 13% alemtuzumab (p=0.0084)&lt;sup&gt;76&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Comparison across clinical trials is impossible due to differences in patient populations, diagnostic definitions, primary and secondary endpoints and outcome metrics.
<table>
<thead>
<tr>
<th>Agent – Intravenous</th>
<th>Effect on Relapse Rate Compared to Placebo or Active Comparator*</th>
<th>Effect on Disability Progression Compared to Placebo or Active Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>mitoxantrone\textsuperscript{157}</td>
<td>66% reduction in annualized relapse rate over two years: 1.02 placebo; 0.35 treated (p=0.001)</td>
<td>Three months confirmed EDSS change during study: 22% placebo; 8% treated (p=0.036)</td>
</tr>
<tr>
<td></td>
<td>Increased 0.23 EDSS over 24 months placebo; Decreased 0.13 EDSS over 24 months 12mg/m\textsuperscript{2} dose [absolute and relative risks not reported]</td>
<td></td>
</tr>
<tr>
<td>natalizumab\textsuperscript{158}</td>
<td>68% reduction in annualized relapse rate over two years: 1 year: 0.78 placebo; 0.27 treated (p&lt;0.001) 2 year: 0.73 placebo; 0.23 treated (p&lt;0.001)</td>
<td>42% decrease in risk of confirmed disability progression Cumulative probability of sustained progression at 2yrs*: 29% placebo; 17% treated (p&lt;0.001)</td>
</tr>
</tbody>
</table>
| ocrelizumab\textsuperscript{159,160} | **Relapsing MS:** Annualized relapse rate*:  
Study 1: IFN 0.292; ocrelizumab 0.156: 46% relative reduction (p<0.0001)\textsuperscript{159}  
Study 2: IFN 0.290; ocrelizumab 0.155: 47% relative reduction (p<0.0001)\textsuperscript{159} | **Relapsing MS:** Proportion of patients with 12-week confirmed disability progression: 9.8% ocrelizumab; 15.2% IFN (p<0.0001) risk reduction (Studies 1 and 2 - pooled analysis): 40% (p=0.0006)\textsuperscript{159}  
**Primary progressive MS:**  
Study 3: Proportion of patients with 12-week confirmed disability progression*: 39.3% placebo; 32.9% treated: relative risk reduction 24% (p=0.0321)\textsuperscript{160}  
Proportion of patients with 24-week confirmed disability progression: 35.7% placebo; 29.6% treated: relative risk reduction 25% (p=0.04)  
Study 3: Mean change [improved performance] in 25-foot walk performance baseline to week 120: 55.1% placebo; 38.9% treated: relative reduction 29.3% (p=0.04) |

* Comparison across clinical trials is impossible due to differences in patient populations, diagnostic definitions, primary and secondary endpoints and outcome metrics.

N.S.= Not Significant;  

MS relapses produce a measurable and sustained impact on disability.\textsuperscript{112,115} While it remains unclear the extent to which reducing relapses impacts long-term disability levels, it is evident that relapse reduction translates into increased comfort and quality of life, fewer days lost from work and other essential activities of daily life, and reduces the risk of residual deficits.\textsuperscript{112,161}

**Impact on MRI parameters**

MRI is a sensitive indicator of disease activity in relapsing forms of MS that can detect new lesions and predict risk of future clinical changes. Brain MRI is now recommended at least annually for patients with relapsing MS to more accurately measure disease activity and inform therapeutic decision-making – and more often as
needed to address specific clinical questions. The 2018 Revised Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS provides detailed recommendations for the use of MRI in CIS, diagnosis, and ongoing MS management.

Table 3: Disease-modifying therapies: pivotal trial data on MRI parameters (listed alphabetically within route of administration)*

<table>
<thead>
<tr>
<th>Agent - Self-Injected</th>
<th>Effect on Gd+ Lesions*</th>
<th>Effect on New or Enlarging T2 Lesions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>glatiramer acetate</td>
<td>29% reduction in mean total # of new contrast enhancing lesions: 36.8 placebo; 25.96 GA 20mg Cumulative number of Gd lesions at nine months: 17 placebo; 11 GA 20mg (p=0.003) Cumulative number of Gd lesions at months 6 and 12: 1.639 placebo; 0.905 GA 40mg (p&lt;0.0001)</td>
<td></td>
</tr>
<tr>
<td>20mg qd†64 (non-pivotal trial data)</td>
<td>Mean number of total new T2: 13.7 placebo; 9.4 GA 20mg (p&lt;0.003)†64 not reported in PI</td>
<td></td>
</tr>
<tr>
<td>40mg tiw†146</td>
<td>Cumulative new or enlarging T2 at months 6 and 12: 5.59 placebo; 3.65 GA 40mg (p&lt;0.0001)†54,146</td>
<td></td>
</tr>
<tr>
<td>interferon beta-1a subcutaneous†60,147</td>
<td>Median number of active lesions per patient per scan: 2.25 placebo; 0.5 44mcg dose (p&lt;0.0001)†60</td>
<td></td>
</tr>
<tr>
<td>interferon beta-1a intramuscular†148</td>
<td>Median percent change of MRI PD-T2 lesion area at two years: 11% placebo; -3.8% 44mcg dose (p&lt;0.0001)†147</td>
<td></td>
</tr>
<tr>
<td>interferon beta-1b†61</td>
<td>Mean number of contrast-enhancing lesions at two years: 1.65 placebo; 0.80 treated (p=0.05)</td>
<td></td>
</tr>
<tr>
<td>peginterferon beta-1a†64</td>
<td>Median percent change T2 lesion volume from study entry to year two: -6.55% placebo; -13.2% treated (N.S.)</td>
<td></td>
</tr>
<tr>
<td>peginterferon beta-1a†64</td>
<td>No Gd outcomes from phase III pivotal trial</td>
<td></td>
</tr>
<tr>
<td>peginterferon beta-1a†64</td>
<td>Median percent change in MRI area (n=52, scans q 6wks): 16.5% placebo; -1.1% 0.25mg dose (p&lt;0.0001)</td>
<td></td>
</tr>
<tr>
<td>peginterferon beta-1a†64</td>
<td>Mean number of contrast enhancing lesions at 48 wks: 1.4 placebo; 0.2 treated (p&lt;0.0001)</td>
<td></td>
</tr>
<tr>
<td>peginterferon beta-1a†64</td>
<td>Mean number of new or newly enlarging T2 lesions at 48 wks: 10.9 placebo; 3.6 treated (p&lt;0.0001)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th>Effect on Gd Lesions*</th>
<th>Effect on New or Enlarging T2 Lesions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>cladribine67</td>
<td>Mean number Gd-enhancing T1 lesions per patient per scan: 0.91 placebo; 0.12 treated (3.5 mg group) (p&lt;0.001)</td>
<td>Mean number active T2 lesions per patient per scan: 1.43 placebo; 0.38 treated (3.5 mg group) (p&lt;0.001)</td>
</tr>
<tr>
<td>dimethyl fumarate150,151</td>
<td>Study 1: Mean number of Gd+ lesions at two years: 1.8 placebo; 0.1 240mg bid dose (p&lt;0.0001)150 Study 2: Mean number of Gd+ lesions at two years: 2.0 placebo; 0.5 240mg bid dose (p&lt;0.0001)151</td>
<td>Study 1: Mean number of new or enlarging T2 lesions at two years: 17 placebo; 2.6 240mg bid dose (p&lt;0.0001)150 Study 2: Mean number of new or enlarging T2 lesions at two years: 17.4 placebo; 5.1 240mg bid dose (p&lt;0.0001)151</td>
</tr>
<tr>
<td>fingolimod152,153</td>
<td>Study 1: Mean number of T1 Gd+ lesions at month 24: 1.1 placebo; 0.2 0.5mg dose (p&lt;0.001)152 Study 2: Mean number of T1 Gd+ lesions at month 24: 1.2 placebo; 0.4 0.5mg dose (p&lt;0.0001)153</td>
<td>Study 1: Mean number of new or newly enlarging T2 lesions over 24 months: 9.8 placebo; 2.5 0.5mg dose (p&lt;0.001)152 Study 2: Mean number of new or newly enlarging T2 lesions over 24 months: 8.9 placebo; 2.3 0.5mg dose (p&lt;0.0001)153</td>
</tr>
<tr>
<td>siponimod71</td>
<td>Cumulative number of Gd lesions up to/including month 24 (adjusted mean): 0.60 placebo; 0.08 treated (p&lt;0.0001)</td>
<td>Mean number of new or enlarging T2 lesions over all visits (adjusted mean): 3.60 placebo; 0.70 treated (p&lt;0.0001)</td>
</tr>
<tr>
<td>teriflunomide155</td>
<td>Mean number of Gd+ lesions per scan: 1.331 placebo; 0.261 14mg dose (p&lt;0.0001)155</td>
<td>Median change from baseline in total lesion volume (mL) (T1+T2) at week 108: 1.127 placebo; 0.345 14mg dose (p=0.0003)</td>
</tr>
</tbody>
</table>

*Comparison across clinical trials is unreliable due to differences in patient populations, diagnostic definitions, primary and secondary endpoints, and outcome metrics.
### Agent – Intravenous

<table>
<thead>
<tr>
<th>Agent – Intravenous</th>
<th>Effect on GD+ Lesions*</th>
<th>Effect on New or Enlarging T2 Lesions*</th>
</tr>
</thead>
</table>
| alemtuzumab<sup>75,76</sup>  
*(compared to interferon beta-1a 44mcg tiw)* | Percent of patients with Gd+ lesions at 24 months (tertiary outcome):  
Study 1: 19% IFN; 7% alemtuzumab (p<0.0001)<sup>75</sup>  
Study 2: 23% IFN; 9% alemtuzumab (p<0.0001)<sup>76</sup> | Patients with new or enlarging T2 lesions (tertiary outcome):  
Study 1: 58% IFN; 48% alemtuzumab (p=0.04)<sup>75</sup>  
Study 2: 68% IFN; 46% alemtuzumab (p<0.0001)<sup>76</sup> |
| mitoxantrone<sup>157</sup> | Number of patients with new Gd+ lesions:  
5/32 (16%) placebo; 4/37 (11%) 5mg/m² dose; 0/31 12mg/m² dose (p=0.022) | Change in number of T2 lesions, mean (month 24 minus baseline): 1.94 placebo; 0.68 5mg/m² dose; 0.29 12mg/m² dose (p<0.0001) |
| natalizumab<sup>158</sup> | Median number Gd+ lesions at two years:  
0 placebo; 0 treated | Median number new or enlarging T2 lesions at two years:  
5/32 placebo; 0 treated (p<0.001) |
| Mean number Gd+ lesions at two years:  
1.2 placebo; 0.1 treated (p<0.001)<sup>158</sup> | Mean number new or enlarging T2 lesions at two years:  
11.0 placebo; 1.9 treated (p<0.001)<sup>158</sup> |
| ocrelizumab<sup>159,160</sup>  
*(Relapsing MS: comparison with IFN beta-1a 44mcg tiw)*  
*(Primary progressive MS: comparison with placebo)* | Relapsing MS:  
Mean number of T1 Gd+ lesions per scan:  
Study 1: IFN 0.286; 0.016 ocrelizumab: 94% relative reduction (p<0.0001)<sup>159</sup>  
Study 2: IFN 0.416; 0.021 ocrelizumab: 95% relative reduction (p<0.0001)<sup>159</sup> | Relapsing MS:  
Mean number of new and/or enlarging T2 lesions per scan:  
Study 1: 1.413 IFN; 0.323 ocrelizumab: 77% relative reduction (p<0.0001)<sup>159</sup>  
Study 2: 1.904 IFN; 0.325 ocrelizumab: 83% relative reduction (p<0.0001)<sup>159</sup> |
| Primary progressive MS: | Study 3: Mean change in volume (cm<sup>3</sup>) of T2 lesions from baseline to week 120: 0.79 placebo; -0.39 treated (p<0.0001)<sup>80</sup> | Mean percent change in brain volume from week 24 to 120: -1.09 placebo; -0.90 treated (p=0.02)<sup>160</sup> |

*Comparison across clinical trials is unreliable due to differences in patient populations, diagnostic definitions, primary and secondary endpoints, and outcome metrics.


After the pivotal trials, several investigations have demonstrated an impact of treatment on the evolution of persistent T1 hypointensities (known as “black holes”) – which are associated with disability as measured by EDSS and considered to be indicative of tissue damage – and on changes in brain volume:

- In a placebo-controlled trial with monthly cerebral MRI, glatiramer acetate was shown to limit the evolution of newly formed lesions into chronic black holes.<sup>165</sup>
• In a phase III trial comparing BG-12 with placebo, which also included glatiramer acetate as an active reference arm, BG-12 and glatiramer acetate significantly reduced the numbers of new T1 hypointense lesions as compared with placebo.\textsuperscript{151}

• Data analysis from phase III clinical trials and subsequent studies demonstrate a variable effect on brain atrophy.\textsuperscript{75,76,152,153,166–172} Table 4 summarizes the impact of disease-modifying therapies on brain volume loss (BVL) in relapsing-remitting patients in phase III clinical trials – with the following caveats: comparisons across studies cannot be made due to differences in assessment measures and study design; and current methods of MRI brain atrophy quantification provide sufficient precision for cohort studies but are not adequate for assessing changes in individual patients over months or a few years.

Of note, in a two-year, placebo-controlled trial, brain atrophy was greater in year one and less in year two in natalizumab-treated patients,\textsuperscript{145} leading some researchers to suggest that the brain atrophy seen in year one may have been “pseudoatrophy” – a reduction in sub-clinical inflammation in response to treatment. However, De Stefano and Arnold\textsuperscript{173} assert that a complete understanding of pseudoatrophy requires further study to clarify the possible underlying pathology.

Table 4: The effect of DMTs on BVL in relapsing patients in phase III trials.

<table>
<thead>
<tr>
<th>Agent – Self-Injected</th>
<th>Changes in Brain Volume Loss</th>
<th>Year 0-1</th>
<th>Year 1-2</th>
<th>Year 0-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>glatiramer acetate\textsuperscript{166,174–176}</td>
<td>× (Eur/Canadian GA trial)</td>
<td>40% reduction vs. placebo (Eur/Canadian GA trial)</td>
<td>✓</td>
<td>× (Eur/Canadian GA trial)</td>
</tr>
<tr>
<td></td>
<td>8% reduction vs. SC IFN-β-1a (REGARD)*</td>
<td>22% reduction vs. SC IFN-β-1a (REGARD)*</td>
<td>No sig. difference with GA +/- SC IFN-β-1b (BEYOND)</td>
<td>No sig. difference with GA +/- SC IFN-β-1a (CombiRx)</td>
</tr>
<tr>
<td></td>
<td>No sig. difference with GA +/- SC IFN-β-1a (CombiRx)</td>
<td>No sig. difference with GA +/- SC IFN-β-1b (BEYOND)</td>
<td>No sig. difference with GA +/- SC IFN-β-1a (CombiRx)</td>
<td></td>
</tr>
<tr>
<td>interferon beta-1a IM\textsuperscript{177}</td>
<td>×</td>
<td>✓</td>
<td>55% reduction vs. placebo</td>
<td>✓</td>
</tr>
<tr>
<td>interferon beta-1a SC\textsuperscript{178}</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>interferon beta-1b SC\textsuperscript{179,180}</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agent – Oral</th>
<th>Changes in Brain Volume Loss</th>
<th>Year 0-1</th>
<th>Year 1-2</th>
<th>Year 0-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>cladribine\textsuperscript{67}</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% brain volume change/year</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>14% (3.5 mg/kg) and 13% % (5.25 mg/kg) vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[months 1-6 excluded to avoid pseudoatrophy confound] (CLARITY)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dimethyl fumarate\textsuperscript{181,182}</td>
<td>–</td>
<td>21% reduction vs. placebo (DEFINE)</td>
<td>21% reduction vs. placebo (DEFINE) ‡</td>
<td>×‡ (CONFIRM)</td>
</tr>
<tr>
<td>Agent – Intravenous</td>
<td>Changes in Brain Volume Loss</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Year 0-1</td>
<td>Year 1-2</td>
<td>Year 0-2</td>
<td></td>
</tr>
<tr>
<td>alemtuzumab(^{75,76})</td>
<td>–</td>
<td>✓</td>
<td>24-42% reduction vs. IFN-β-1a</td>
<td></td>
</tr>
<tr>
<td>natalizumab(^{168,172})</td>
<td>40% increase vs. placebo (\text{(AFFIRM)})</td>
<td>✓</td>
<td>× (AFFIRM)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19% increase vs. placebo (\text{(SENTINEL)})</td>
<td>×</td>
<td>× (\text{(SENTINEL)})</td>
<td></td>
</tr>
<tr>
<td>siponimod(^{71})</td>
<td>✓ 0.18% adjusted mean reduction vs. placebo -0.28% vs. -0.46% (p&lt;0.00001) (\text{(EXPAND)})</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>teriflunomide(^{155})</td>
<td>37% reduction vs. placebo (\text{(TEMSO)})</td>
<td>31% reduction vs. placebo (\text{(TEMSO)})</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4 Abbreviations: AFFIRM: Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis; BEYOND: Betaferon Efficacy Yielding Outcomes of a New Dose; BID: Twice daily; BVL: Brain Volume Loss; CLARITY: Cladribine Tablets Treating Multiple Sclerosis Orally; CombiRx: Combination Therapy in Patients with Relapsing-Remitting Multiple Sclerosis; CONFIRM: Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis; DEFINE: Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting Multiple Sclerosis; DMTs: Disease-Modifying Therapies; EXPAND: Siponimod versus Placebo in Secondary Progressive MS; GA: Glatiramer Acetate; IFN: Interferon; IM: Intramuscular; OPERA 1 & 2: Ocrelizumab vs. Interferon Beta-1a in Relapsing Multiple Sclerosis; REGARD: The Rebif vs Glatiramer Acetate in Relapsing MS Disease; RRMS: Relapsing-Remitting Multiple Sclerosis; SC: Subcutaneous; SENTINEL: The Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis; TEMSO: Teriflunomide Multiple Sclerosis Oral; TID: Three Times Daily; TRANSFORMS: Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis.

Table 4 Symbols:
- Data not reported/available.
- \(\times\) No significant effect or not statistically significant.
- ✓ Significant effect.
- \(\checkmark\) Not all approved therapies have significant effects on BVL and effects can be delayed until the second year of therapy.
- + No P value reported.
- †Significant effect at 9–18 months.
- ‡Significant effect at 6–24 months in DEFINE (only BID, not TID dose arm), but not in CONFIRM study.
- §Significant effect also seen at 0–6 months.
Table 4 was adapted from the following source: Alroughani et al. Copyright: Alroughani R, Deleu D, El Salem K, Al-Hashel J, Alexander KJ, Abdelrazeq MA, Aljishi A, Alkhabooori J, Al Azri F, Al Zadjali N, Hbahbih M, Sokrab TE, Said M, Rovira A. 2016. BMC Neurology. Reproduced via Open Access under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

**Head-to-head comparison data in relapsing MS**

In addition to the active comparator registration trial data reported in Table 2, the following comparison trials have been reported:

- **IFNB-1a 44 mcg tiw vs. IFNB1a weekly (EVIDENCE):** A prospective, 24-week, randomized, controlled, multi-center trial of 677 RRMS patients demonstrated superior efficacy in favor of IFNB-1a tiw in the number of relapse-free patients (p=0.0005) and active MRI lesions (p<0.001).\(^\text{184}\)

- **IFNB-1a IM weekly + GA 20 mg SC daily vs. IFNB-1a IM weekly or GA 20 mg SC daily (CombiRx):** A double-blind, randomized, controlled study that followed patients for a minimum of three years found: the combination to be significantly better than IFN alone in reducing the risk of relapse and superior to either agent alone in reducing new lesion activity and accumulation of total lesion volume; GA to be significantly better than IFN in reducing the risk of relapse; the combination to be no better than either agent alone in reducing progression.\(^\text{185}\)

- **IFNB-1b vs. GA (BECOME):** A prospective, randomized, single-blind (MRI rater), one-year study of 75 RRMS patients demonstrated no difference in MRI outcomes.\(^\text{186}\)

- **IFNB-1b 250 mcg or 500 mcg vs. GA (BEYOND):** A prospective, randomized, multi-center study of 2244 RRMS patients over 2-3.5 years demonstrated no difference in relapse rate, EDSS progression and MRI outcomes.\(^\text{166}\)

- **Oral BG12 (dimethyl fumarate) (240 mg bid and tid) vs. GA (reference comparator) (CONFIRM):** A prospective placebo-controlled phase III, randomized trial of 1417 RRMS patients with GA as a reference comparator demonstrated the superiority of all three agents relative to placebo on risk of relapse (BG12 bid p=0.002; BG12 tid p<0.001; GA p=0.01); no significant reduction in disability progression for any of the agents; all agents superior to placebo on MRI outcomes p<0.001.\(^\text{151}\)

- **IFNB-1b vs. IFNB-1a weekly (INCOMIN):** A prospective, 2-year, randomized, multi-center trial of 188 RRMS patients demonstrated superior efficacy in favor of IFNB-1b on risk of relapse (p=0.003) and MRI outcomes (p<0.0003).\(^\text{187}\)

- **IFNB-1a tiw vs. GA (REGARD):** A prospective, randomized, comparative, parallel-group, open-label study of 764 RRMS patients demonstrated no difference between groups in time to first relapse and no significant differences for MRI outcomes except IFNB-1a patients had significantly fewer enhancing lesions (p=0.0002).\(^\text{176}\)

- **Teriflunomide vs. IFNB-1a tiw (TENERE):** A prospective, randomized, controlled, phase III, multi-center rater-blinded trial of 324 RRMS patients demonstrated: no difference in the primary outcome of time to failure (first appearance of confirmed relapse or permanent treatment discontinuation for any cause); and no difference in ARR (secondary outcome) between teriflunomide 14 mg and IFNB-1a, but ARR was higher with teriflunomide 7 mg vs. IFB-1a (p=0.03).\(^\text{188}\)

- **Fingolimod vs. INFb-1a weekly (TRANSFORMS):** A prospective, 12-month, double-blind, randomized trial of 1153 RRMS patients demonstrated superior efficacy in favor of fingolimod with respect to relapse rate (p<0.001) and MRI outcomes (p<0.001).\(^\text{154}\)

- **Ocrelizumab vs. IFNB-1a tiw (OPERA I and II) demonstrated the superiority of ocrelizumab in annualized relapse rate and MRI outcomes, as well as disability progression (pooled analysis) (see Tables 2 and 3).**\(^\text{159}\)

Additional studies comparing various agents provide important information for healthcare providers and patients who are making complex treatment decisions:

- A large international, observational, prospectively acquired cohort study looking at relapse and disability outcomes in 792 RRMS patients who had disease activity while on IFN beta or GA and switched to either natalizumab or fingolimod, demonstrated a post-switch difference in relapse hazard...
Evidence Demonstrating the Impact of Treatment on Progressive MS

Many agents have been investigated for use in secondary progressive or primary progressive MS. Sub-group analyses from some of these clinical trials indicated benefits in patients of younger age with more recent progression, recent relapse and/or MRI activity. Mitoxantrone, which is seldom used in the United States because of its high risk profile, has an FDA indication for secondary progressive MS. Cladribine and siponimod are both indicated for active secondary progressive MS. Only ocrelizumab has FDA approval for primary progressive MS. The remaining medications are approved for relapsing forms of MS, including progressive MS in those patients who experience relapses or MRI activity.

Impact on long-term clinical outcomes

In addition to being expensive and difficult, it is unethical in the current treatment era to carry out long-term randomized controlled studies to assess the value of disease-modifying treatment compared to placebo on the course of MS. Hence, alternate methods for studying natural history in the treatment era need to be employed. Following an observational cohort of people over an extended period has limitations, including non-randomized design, difficulty accounting for dropouts and, in some studies, retrospective assessments conducted on individuals seen at divergent time periods. However, important data have emerged demonstrating that early and ongoing treatment has a significant impact on long-term clinical outcomes:

- In a cohort observational study of 3,060 patients, disease-modifying therapies delayed long-term disability, as measured by the EDSS, in patients treated either early or, to a lesser extent, in the later phase of the disease compared to untreated patients.
- In a longitudinal prospective study of newly-diagnosed MS patients at Karolinska Hospital between 2001-2005, early treatment was correlated with longer time from diagnosis to EDSS \( \geq 4 \).
- The 10-year follow-up of the early intervention trial with interferon beta-1a (intramuscular) found a delayed conversion to clinically definite MS and reduced relapse rates in the early treated group compared to the delayed treatment group, but no difference in disability outcomes, most likely because both groups received treatment relatively early in the disease course.
- In a nine-year follow-up of the pivotal phase III teriflunomide trial (TEMSO), a positive effect on disease activity persisted in the original treatment group as well as in the placebo patients who switched to active treatment in the open-label extension.
- A long-term follow-up (greater than seven years) from the phase III study of oral cladribine (CLARITY) demonstrated a persistent positive effect on relapse and MRI activity.
• The 2-year extension study from the phase III (CLARITY) demonstrated a sustained impact on MRI outcomes and annualized relapse rate.199,200
• Approximately 90 percent of untreated RRMS patients will have SPMS after 15-26 years.201,202 Evidence from several studies now indicates that disease-modifying therapies have an impact on the conversion from relapsing to progressive MS:
  - In a study comparing the time interval from disease onset to secondary progression in relapsing-remitting patients treated with disease-modifying therapy and patients receiving no treatment, a significantly longer time to secondary progression was seen in the treated group.203
  - A study comparing treated and untreated patients over a 10-year period prior to the endpoint of conversion to secondary progressive MS found that treatment with a disease-modifying therapy significantly reduced the risk of disease progression in patients considered high- or low-risk at disease onset.204
  - In a study comparing patients treated with interferon beta for up to seven years with untreated patients, the treated group had a significant reduction in the incidence of secondary progression as well as in the incidence of EDSS progression.205
  - In a single center prospective observational study of 517 actively treated relapsing MS and CIS patients at a median time point of 16.8 years after disease onset, only 10.7 percent reached an EDSS ≥6.0, and 18.1 percent evolved to secondary progressive MS.206

• The impact of early treatment on other clinical outcomes is also important. Extension study data from the early treatment trial with interferon beta-1b suggest that early treatment helps to preserve cognitive function compared to delayed treatment,207,208 with evidence suggesting that long-term (physical and cognitive) outcomes may be largely determined early in the disease course.118 Another study demonstrated decreased mortality in patients treated early in the course of their disease compared with those treated later,15 a finding that needs to be confirmed with the newer agents in long-term studies.
• Most of the extension studies from the pivotal trials indicated a positive impact on time to a second attack or new lesions, relapse rates and disease progression,118,140,174,207 although much of the impact has been thought to take place early in the disease course.118 In a more recent study, using data extracted from the global MSBase Registry, Jokubaitis and colleagues115 examined median EDSS score changes in 2,466 relapse-onset patients initially treated with either interferon-beta or glatiramer acetate. The patients (including those who stayed on their initial treatment, those who switched to other therapies and those who stopped treatment altogether) were treated an average of 83 percent of the follow-up period. The cumulative time on treatment was independently associated with a lower EDSS score at 10 years, demonstrating that increased exposure to treatment predicts better disability outcomes in the long-term. The authors also found that annualized relapse rate was the strongest predictor of increases in median EDSS scores, with on-therapy relapses being more predictive than off-therapy relapses – and concluded that persistent relapse activity on a first-line therapy is prognostic of increasing disability.

Impact on NEDA (no evidence of disease activity)

NEDA is a term used to describe disease stability, including no new relapses, no disability progression and no new or enlarging MRI lesions.209,210 In addition, some researchers have proposed adding no additional brain volume loss to this definition (NEDA-4).211,212 Post-hoc analysis of several MS treatment trials has suggested that the goal of NEDA may be achievable for some individuals.209,210,213 The evidence to date suggests that NEDA is difficult to sustain over the long term even with treatment. On the basis of their seven-year longitudinal study, Rotstein and colleagues conclude that NEDA status at two years may be a good predictor of long-term disease stability and may be useful as a treatment outcome in investigations of new treatments for MS.210

However, in a prospective single center observational study of 517 actively treated relapsing MS patients, NEDA at two years was not associated with better long term measures of disability by EDSS.206 In the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b study patients, NEDA based on clinical features
predicted long-term disability outcome; however adding MRI changes to the NEDA criteria did not increase predictive validity.\textsuperscript{214}

Although NEDA is a compelling concept and shared goal among people with MS and their healthcare providers, no consensus has yet emerged for the role of NEDA in making clinical decisions.

**Impact on quality of life**

Clinical and MRI outcomes do not fully capture the impact of MS disease-modifying therapies for people with MS. Unfortunately, efforts to assess the impact of treatment on quality of life have been limited. In one study of newly-diagnosed patients beginning treatment with an interferon medication, quality of life scores on the MSQoL-54 showed overall improvement at 12 months.\textsuperscript{215}

Not being on a disease-modifying therapy was one of the factors identified as contributing to a decrease in health-related quality of life in the NARCOMS database, although quality of life generally remained fairly stable for most people over the five years of the study.\textsuperscript{216} Health-related quality of life scores on physical and mental components of the Short Form (36) Health Survey (SF-36 – a patient-reported survey of health outcomes) improved in the pivotal trials of natalizumab.\textsuperscript{217} In the pivotal trial of dimethyl fumarate, patients on treatment evidenced a significant improvement in SF-36 physical component summary scores compared with placebo-treated patients whose scores worsened, and similar benefits were seen in other measures of functioning and general well-being as early as week 24.\textsuperscript{218}

Early treatment to reduce loss of mobility has been shown to help preserve people’s ability to carry out instrumental activities of daily living,\textsuperscript{219} and the ability to work was found to improve after one year of treatment with natalizumab.\textsuperscript{220}

In a review of existing data on the relationship between inflammation, patterns of CNS lesions and the effects of immunotherapeutics on MS fatigue, the disease-modifying therapies were observed to “effectively and sustainably stabilize and ameliorate fatigue in parallel to their dampening effects on the neuroinflammatory process.”\textsuperscript{221}

**Benefits gained through early treatment may never be equaled in those whose treatment is delayed**

Data suggest that benefits gained through early treatment, including delay of a second clinical event or MRI activity in CIS patients, reduced relapse rates and disability, may not be equaled in those who start treatment later in the disease course,\textsuperscript{92,94,115,196,222–225} suggesting that people who start treatment later may not “catch up” with those who start treatment immediately.

As stated earlier however, the 10-year follow-up to the early intervention trial with interferon beta-1a (intramuscular) found no difference in disability outcomes between the early- and delayed-treatment groups, indicating that the delayed treatment group did appear to experience a “catch up” in this particular outcome.\textsuperscript{196} It remains to be determined the extent to which the older medications – and the newer medications for which we have limited long-term data – impact longer-term disability outcomes for people with MS. Similarly, 11-year follow-up data on the CIS cohort treated with interferon beta-1b or placebo for up to two years prior to open label active therapy demonstrated no significant difference in EDSS outcome between groups.\textsuperscript{226}

**Evidence Supporting the Need for Treatment to be Ongoing**

Once a disease-modifying treatment is initiated, evidence suggests that treatment needs to be ongoing for benefits to persist. Cessation of treatment has been shown to negatively impact clinical and MRI outcomes.

- Non-adherence and gaps in treatment are associated with an increased rate of relapses and progression of disability.\textsuperscript{227,228}
- In a review of studies looking at treatment discontinuation, Tobin and Weinshenker concluded that discontinuation of treatment early in MS could lead to re-emergence of disease activity. The impact of treatment discontinuation in patients over the age of 60 with long-term progressive disease is less clear.\textsuperscript{229}
• In a review of the adherence results, relapse rate and progression were greater in those who stopped injectable disease-modifying treatment, and several reviewed trials showed an increase in emergency department utilization by patients who had stopped treatment.230
• In one study, relapses and MRI activity returned to baseline following cessation of interferon therapy, although there was a several month refractory period before activity resumed.231 In another study, active patients treated with interferon beta promptly returned to pre-treatment levels of disease activity following discontinuation of treatment,232 leading the authors to recommend that treatment not be stopped in patients who are responding to treatment. A similar return to baseline disease activity in interferon-treated patients was observed in secondary progressive MS, with an increase in EDSS scores and MRI activity in the year after discontinuation of treatment.233
• Relapse rates returned to baseline following interruption of natalizumab treatment in three large studies,234 and in a partially placebo-controlled exploratory study of disease activity during an interruption of natalizumab therapy, patients whose treatment was interrupted had an increased risk of disease and MRI activity compared with those on continuous treatment.235 In a retrospective study of patients refractory to interferon or glatiramer who had been switched to natalizumab and then stopped it, some patients had significant relapses – indicating that simple withdrawal of this medication without early implementation of an alternative treatment strategy may risk return of disease activity or rebound, typically within the first six months.223,236–238 In a study of 32 patients with MS who stopped natalizumab treatment, rebound was identified with an increase in relapses and high MRI activity compared to baseline.239
• Cessation of fingolimod after a period of stability was followed by clinical relapse and multiple enhancing lesions on MRI in two patients,240 and both patients had a significant worsening in EDSS scores associated with their clinical activity. In another report of six cases of fingolimod discontinuation, five patients returned to pre-treatment disease activity within three months, and one patient had both clinical and MRI rebound activity.241 A recent review reported five individuals experiencing increased disease activity within 4–16 weeks following discontinuation of fingolimod therapy (10.9 percent of 46 patients discontinuing the drug during the two-year observation period) and identified 11 other reported cases of rebound disease activity.242
• Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator (fingolimod) similar to siponimod.243

These studies and case reports illustrate the need for ongoing disease-modifying treatment in MS. Regardless of the reason for the discontinuation of treatment – a decision by the treating clinician, patient non-adherence, cost or insurance coverage issues – these findings indicate that discontinuation or interruption of treatment will provoke a return of disease activity in many people.

Situations in which discontinuation of treatment might be considered

While there is ample evidence to support the benefits of ongoing treatment for the majority of people with MS, there may be some situations in which clinicians and their patients might consider stopping treatment.82 In a 2015 review of relevant studies, Tobin and Weinshenker229 conclude that although freedom from subsequent relapse is impossible to guarantee, treatment cessation may be considered in patients who:

• Are over 60 years of age
• Have experienced a progressive disease course for five years or longer
• Have no accumulating T2 lesions or gadolinium enhancing lesions on MRI of the brain or spinal cord after a period of observation over several years

Earlier discontinuation, particularly in patients with active disease, may lead to increased disease activity. Clinical and MRI monitoring for recurrent disease activity is clearly warranted in those patients.

Use of Disease-Modifying Therapies in Pediatric MS
Studies have estimated the incidence of pediatric MS to be between 0.18 and 0.51/100,000 children per year.243,244 Three to 10 percent of adult patients retrospectively report a possible first attack prior to age 18.245
More than 97 percent of children and adolescents experience a relapsing-remitting disease course,\textsuperscript{243} with annualized relapse rates 2-3 times that of adults with MS during the first three years of disease.\textsuperscript{246} In addition to motor and other physical symptoms that occur during relapse (and often resolve with relapse therapy), 30-40 percent of children with MS demonstrate cognitive impairment early in the disease course.\textsuperscript{130-132}

The interferon beta medications and glatiramer acetate have traditionally served as the initial treatment options for children with MS.\textsuperscript{243,247} The recently completed PARADIGMS trial, a double-dummy randomized trial comparing fingolimod to interferon beta-1a by subcutaneous injection demonstrated a clear superiority of fingolimod over interferon (82 percent reduction in relapse rate). Superiority of fingolimod was also demonstrated by MRI endpoints. The FDA has now approved fingolimod for pediatric MS, the first FDA approval for any MS therapy in this age group. While data regarding how the PARADIGMS results will alter clinical practice have yet to be accrued, the option of oral therapy will appeal to many children. Safety considerations, however, must be carefully considered. Structured screening protocols, such as ensuring up to date vaccination status (notably confirmation of vaccination against varicella zoster), ophthalmological and dermatological evaluations, and monitoring for first-dose effect bradycardia are critical. Pediatric centers may need to partner with adult MS centers to ensure consistent care programs for fingolimod use.

As in adults, however, evidence of ongoing relapses, MRI activity, and increasing disability (which is less common in pediatric MS patients) indicate the need to escalate to higher potency therapies. Considerations include switching from interferon or glatiramer acetate to oral or infused medications.\textsuperscript{247} In one study involving 258 children over a mean observation period of 3.9 years, a little more than half were successfully managed on the first medication they were given, while 25.2 percent were switched once, 11.2 percent were switched twice, and 7.8 percent required three changes in medication. While some were switched from one injectable medication to another, others required more aggressive treatment in order to control their disease.\textsuperscript{247} Several retrospective analyses regarding safety and tolerability of natalizumab support the use of natalizumab in pediatric MS patients with active or aggressive disease.\textsuperscript{248–251} Case report and case series data have advocated use of rituximab for patients requiring escalation of therapy,\textsuperscript{252–254} while future study of ocrelizumab in pediatric MS patients is awaited.

The importance of high quality data regarding therapeutic safety and efficacy has been emphasized\textsuperscript{243} and pediatric clinical trials of all new agents are mandated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).\textsuperscript{255–257} The PARADIGMS trial not only informed on the impact of fingolimod vs. interferon beta-1a on clinical and MRI disease activity in pediatric MS patients, it also provided new insight into the challenges of pediatric MS clinical trials. Enrollment took longer than anticipated, a multinational site study was required owing to the rarity of pediatric MS, and the burden of rigorous clinical trial monitoring and visits challenged patients, parents and providers. Nonetheless, it is imperative to determine how best to ensure that all trials produce informative data on therapeutic safety and efficacy, and the International Pediatric Multiple Sclerosis Study Group is preparing a working group manuscript that addresses these key considerations.

It is noteworthy that access to certain medications for pediatric MS patients in some world regions may be limited by regulation. It is hoped that clinical trial data will enhance regulatory approval and access.

**Treatment Considerations in Women and Men in Their Reproductive Years**
None of the FDA-approved disease-modifying therapies are approved for use during pregnancy or breastfeeding (see Table 5). Several observational studies, including pregnancy registries, have been done to identify potential risks of the disease-modifying therapies for fetal development and breastfeeding.\textsuperscript{258–260}

<table>
<thead>
<tr>
<th>AGENT -- INJECTABLE</th>
<th>PREGNANCY INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glatiramer acetate</td>
<td>Should be used during pregnancy only if clearly needed</td>
</tr>
<tr>
<td>(Copaxone)</td>
<td></td>
</tr>
<tr>
<td>(Glatopa)</td>
<td></td>
</tr>
<tr>
<td>(Glatiramer acetate injection)</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Pregnancy information for the FDA-approved disease-modifying therapies*
<table>
<thead>
<tr>
<th>Interferon beta-1a (Avonex)</th>
<th>Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon beta-1a (Rebif)</td>
<td></td>
</tr>
<tr>
<td>Interferon beta-1b (Betaseron; Extavia)</td>
<td></td>
</tr>
<tr>
<td>Pegylated interferon (Plegridy)</td>
<td></td>
</tr>
</tbody>
</table>

**AGENT -- ORAL**

<table>
<thead>
<tr>
<th>Dimethyl fumarate (Tecfidera)</th>
<th>Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fingolimod (Gilenya)</td>
<td></td>
</tr>
</tbody>
</table>

**AGENT -- INTRAVENOUS**

<table>
<thead>
<tr>
<th>Alemtuzumab (Lemtrada)</th>
<th>Should be used in pregnancy only if the potential benefit justifies risk to the fetus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitoxanthrone (Novantrone)</td>
<td>Women of childbearing potential should be advised to avoid becoming pregnant.</td>
</tr>
<tr>
<td>Natalizumab (Tysabri)</td>
<td>Natalizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</td>
</tr>
<tr>
<td>Ocrelizumab (Ocrevus)</td>
<td>There are no adequate data on the developmental risks associated with use of Ocrevus (ocrelizumab) in pregnant women.</td>
</tr>
</tbody>
</table>

*Table adapted from Academy of Neurology Practice Guideline: Disease-Modifying Therapies for Adults with Multiple Sclerosis*[^52]

- Glatiramer acetate does not cross the placenta and is likely safe for use during breastfeeding.⁴²⁵⁸ Confirming earlier findings in small studies,⁴²⁶¹ a prospective cohort study of 246 pregnancies (from the German Multiple Sclerosis and Pregnancy Registry), in which 151 women were exposed to glatiramer acetate (pregnancy category B) and 95 were taking no disease-modifying therapy, found no impact on several major pregnancy outcomes (risk for congenital anomaly, lower birth weight, pre-term birth or spontaneous abortion).⁴²⁶²
• Beta-interferon crosses the placenta in minimal quantities; it is unknown whether it is excreted in breast milk.\textsuperscript{263} Using the same German Multiple Sclerosis and Pregnancy Registry database, a prospective study of 445 pregnancies, in which 251 women were exposed to interferon-beta and 194 were taking no disease-modifying therapy, found no differences in mean birth weight and length, pre-term birth, spontaneous abortion or congenital anomalies.\textsuperscript{264}

• Teriflunomide carries a boxed warning about the risk of teratogenicity (see Table 1). This medication crosses the placenta; it is unknown whether it is excreted in human milk.\textsuperscript{72} A study of 105 pregnancy exposures (83 female and 22 male) to teriflunomide for varying lengths of time found no increase in spontaneous abortion rate or fetal abnormalities.\textsuperscript{265} A rapid elimination program using oral cholestyramine over several days is recommended for women to lower teriflunomide levels to less than 0.02 µg/ml. Men taking teriflunomide should stop the medication before trying to conceive and discuss rapid elimination with their healthcare providers. The 2018 AAN Practice Guideline includes a Level B recommendation that clinicians should counsel men with MS regarding the implications of their treatment decisions for their reproductive plans before initiating treatment with a chemotherapeutic agent such as teriflunomide or cyclophosphamide. Refer to AAN.com/guidelines.\textsuperscript{82}

• Fingolimod crosses the placenta and is excreted in breastmilk. A pregnancy registry is ongoing and patients are advised to use effective contraception and wait at least two months before attempting conception.\textsuperscript{59}

• It is unknown whether dimethyl fumarate crosses the placenta or enters breastmilk.\textsuperscript{68} Animal studies of teratogenicity have shown conflicting results.\textsuperscript{259} Because of its short half-life (approximately one hour), no washout may be necessary.\textsuperscript{68,260}

• Natalizumab crosses the placenta and is excreted in breast milk.\textsuperscript{70,258} Compared with historical controls, no significant difference has been found in the rate of fetal malformations in MS and Crohn’s clinical trial programs or the Tysabri Pregnancy Exposure Registry.\textsuperscript{266}

• Mitoxantrone crosses the placenta in limited amounts and is excreted in breast milk.\textsuperscript{78} Patients should be instructed not to become pregnant while taking mitoxantrone and for at least six months after discontinuation.\textsuperscript{258}

• Alemtuzumab crosses the placenta; it is not known whether it is excreted in breast milk. Because alemtuzumab has the potential for serious adverse reactions in infants, women should be advised not to breastfeed while on this medication.\textsuperscript{74} There are no adequate and well-controlled studies in pregnant women.\textsuperscript{74}

• Ocrelizumab is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier. Following administration to pregnant monkeys, at doses 2-10 times the approved human dose by weight, increased perinatal mortality, depletion of B-cell populations, renal, bone marrow and testicular toxicity were observed in the offspring. Women of childbearing age should use contraception while receiving ocrelizumab and for six months after the last dose. There are no data on the presence of ocrelizumab in human milk; it is excreted in the milk of ocrelizumab-treated monkeys. Human IgG is excreted in human milk, and the potential for absorption of ocrelizumab to result in B-cell depletion in infants is unknown.\textsuperscript{80}

• Cladribine is contraindicated in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception.\textsuperscript{66}

• Women taking siponimod should use effective contraception during treatment and for 10 days after stopping treatment.\textsuperscript{70}

• Although there are no data on the presence of siponimod in human milk, a study in lactating rats has shown excretion of siponimod and/or its metabolites in milk.

The current standard of care is to avoid the use of disease-modifying therapies during pregnancy and breastfeeding.\textsuperscript{259–261,267–270} Based on exponential decay, the commonly accepted timeframe for drug discontinuation before conception is five maximal half-lives—approximately two to six weeks\textsuperscript{269} with two months recommended for fingolimod and at least three months for natalizumab.\textsuperscript{267} However, there is increasing evidence that glatiramer acetate and interferon-beta may be continued safely during conception and pregnancy in a woman with very active disease.\textsuperscript{267,268,271–273} The risks and benefits of continuing therapy during pregnancy require careful discussion, taking into account the level of disease activity, personal preferences and
the patient’s and doctor’s risk tolerance. Similarly, a discussion about the risks and benefits of postponing resumption of treatment in order to breastfeed is important, particularly for women who had active disease in the year prior to conception. In a recent study, natalizumab started within eight days of delivery successfully prevented post-partum relapses in five of six women with very active disease.

Rationale for Access to the Full Range of Treatment Options
At present, 17 medications are FDA-approved to treat MS (See Table 1), with ten different mechanisms of action that are thought to address distinct components of the immune-mediated disease process. These medications also differ in their route and frequency of administration as well as their side effects and risk profiles. None of these medications are curative and the efficacy of any given medication varies considerably from one individual to another and for any given individual at different points in time. In addition, people with MS differ in their tolerance for different routes of administration and side effects, and clinicians and patients vary in their tolerance for risk, with risk tolerance likely undergoing shifts as the disease progresses. Access to the full range of options is essential to optimal management, for the following nine reasons.

1. Non-responders need access to other options

The goal of treatment is to control disease activity and prevent irreversible damage as quickly and effectively as possible. When a person’s medication does not provide sufficient suppression of disease activity or provides initial benefit and then ceases to do so – as determined by the individual and his or her clinician in light of continued clinical and/or MRI disease activity – the reasons for lack of efficacy need to be explored and alternative options need to be considered. It is known, for example, that disease activity which occurs in spite of treatment with IFN beta or GA is associated with unfavorable long-term outcomes. Furthermore, MRI activity as well as relapses are key indicators of progression and the presence of Gd-enhancing lesions has been shown to correlate with worsening disability after 15 years.

2. The effort to achieve NEDA requires access to the full range of treatment options

To achieve NEDA or the lowest possible level of subclinical disease activity, the authors of “Brain Health: Time Matters in Multiple Sclerosis” (endorsed by the MS Coalition) recommend swift action in the face of disease activity, including consideration of switching to another disease-modifying therapy with a different mechanism of action.

3. Treatment with interferon beta and natalizumab is associated with the development of neutralizing antibodies (NAbs)

Although comparisons are challenged by lack of standardization in assays and lack of consensus concerning the relevant threshold of NAb concentration, the phase III trials of the interferon beta medications, as well as subsequent direct comparison studies, have demonstrated that NAbs are a common occurrence with these medications and that there is significant variability between the medications in terms of their occurrence. Furthermore, the studies suggest that the presence of NAbs reduces the clinical efficacy of interferon beta – although the impact may not be clear for some time. Determining the impact of NAbs for any given individual is further complicated by the fact that NAb-positive patients may revert to NAb-negative status or fluctuate between positive and negative NAb status. However, the fact remains that a person who has persistent disease activity on interferons, regardless of whether or not this is due to NAbs, requires access to non-interferon treatment options.

In two phase III clinical trials of natalizumab, the incidence of persistent antibody positivity associated with the drug was six percent. Compared with antibody-negative patients, those with persistent antibody positivity had a significantly higher relapse rate and more activity on MRI in both studies, as well as significantly greater disease progression in one of the studies. Persistent antibody positivity was also associated in both studies with a higher incidence of infusion-related adverse events, including hypersensitivity reactions.
Of the 58 percent of patients in a prospective observational study of 73 consecutive patients who developed NAbs, the vast majority reverted to antibody-negative status on follow-up. In this study, the presence of NAbs was inversely correlated with serum natalizumab concentration, and high antibody titers and low serum natalizumab concentrations were associated with an increase in relapses and Gd-enhancing lesions on MRI.

### 4. Individuals at high-risk for PML need access to other options

People who are or become JC antibody-positive need access to treatments that do not put them at risk for PML.

- The boxed warning for **Tysabri** (natalizumab) states that the risk factors for the development of PML include duration of therapy, prior use of immunosuppressants and the presence of anti-JCV antibodies – and that these factors should be taken into account when initiating and continuing treatment with this medication.

- The prescribing information for **Gilenya** (fingolimod) states that the medication should be withheld at the first sign or symptom suggestive of PML. It is not known whether individuals with anti-JCV antibodies taking fingolimod are at higher risk of PML given the limited number of PML cases to date with this agent.

- The prescribing information for **Tecfidera** (dimethyl fumarate) states that the medication should be withheld at the first sign or symptom suggestive of PML. It is not known whether individuals with anti-JCV antibodies taking dimethyl fumarate are at higher risk of PML given the limited number of PML cases to date with this agent.

- A case of PML has been reported in a patient taking teriflunomide who was previously treated with natalizumab.

- The prescribing information for **Ocrevus** (ocrelizumab) states that PML is possible with this medication.

- No cases of PML have been reported in siponimod-treated patients. However, PML has been reported in patients treated with another S1P receptor modulator.

A PML risk stratification for disease-modifying therapies is summarized in Table 6.
TABLE 6: A PML risk stratification table for disease-modifying therapies.*

<table>
<thead>
<tr>
<th>Therapeutic Agent</th>
<th>Treated condition predisposes to PML?</th>
<th>Latency from time of drug initiation to PML</th>
<th>Frequency/Incidence of PML</th>
<th>Year drug introduced into U.S. and European markets</th>
<th>Patients/patient-year (PY) exposures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I – high potential risk of PML</td>
<td>No</td>
<td>Yes</td>
<td>High</td>
<td>U.S. – approved 2004; withdrawn Feb 2005; reintroduced Jun 2006</td>
<td>161,300 patients</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>MS and Crohn’s disease</td>
<td>None &lt; 8 months; &gt; 60% of cases &gt; 24 months</td>
<td>1/100–1/1000</td>
<td>EUR – Apr 2006</td>
<td>(September 30, 2016)</td>
</tr>
<tr>
<td>Class II – low potential risk of PML</td>
<td>No</td>
<td>Yes</td>
<td>Low/infrequent</td>
<td>U.S. – Mar 2013</td>
<td>224,542 patients</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
<td>MS and psoriasis</td>
<td>18–54 months</td>
<td>-1/50,000</td>
<td>Europe – Feb 2014</td>
<td>308,782 PY</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>MS</td>
<td>18–54 months*</td>
<td>-1/18,000</td>
<td>U.S.- Sep 2010</td>
<td>360,000 patients</td>
</tr>
<tr>
<td>Class III – no or very low potential risk of PML</td>
<td>Yes</td>
<td>No</td>
<td>Very low or evident only with related drug</td>
<td>U.S. – Nov 2014</td>
<td>-11,000 patients</td>
</tr>
<tr>
<td>Alemtuzumab</td>
<td>Hematological malignancies, transplantation</td>
<td>Unknown; no cases with MS</td>
<td>U.S. – Sep 2013</td>
<td>MS – unapproved indication</td>
<td>No data</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Lymphoproliferative disorders, rheumatoid arthritis, ANCA-associated vasculitis, SLE</td>
<td>1/30,000</td>
<td>EUR – Oct 2006</td>
<td></td>
<td>No data</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>No PML observed with teriflunomide, but related leflunomide</td>
<td></td>
<td>U.S.- Sep 2012</td>
<td>68,952 patients</td>
<td></td>
</tr>
<tr>
<td>Daclizumab</td>
<td>No PML observed with MS or as monobehaviour for neoclonal</td>
<td></td>
<td>U.S.- Aug 2013</td>
<td>96,509 PY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>U.S.- May 2016</td>
<td>1316 patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EUR-Jul 2016</td>
<td>3744 PY</td>
<td></td>
</tr>
</tbody>
</table>

*This table and the associated paper were published prior to the FDA-approval of ocrelizumab, siponimod and mavenclad. However, the prescribing information for ocrelizumab states that PML has been seen in patients treated with other anti-CD20 antibodies.

Legend PY - Patient year exposure.
U.S. – United States.
EUR - Europe.
# - Data on file with respective manufacturer as of submission date.

*Printed with permission of the publisher*

5. **Individuals with contraindications need access to suitable options**

For a variety of reasons (cited as contraindications in medication labeling), individuals may not be suitable candidates for one or another of the available disease-modifying therapies:

- Hypersensitivity to glatiramer acetate or mannitol, precluding the use of glatiramer acetate
- Hypersensitivity to natural or recombinant interferon beta, albumin or other component of the formulation, precluding the use of interferon medications
- Hypersensitivity to dimethyl fumarate or to any of the excipients, precluding the use of dimethyl fumarate
- Cardiac or ocular conditions, or treatment with Class 1a or Class III anti-arrhythmic drugs, precluding the use of fingolimod and siponimod
- Hypersensitivity to fingolimod or its excipients, precluding the use of fingolimod or siponimod
- Current use of leflunomide, precluding the use of teriflunomide
- Infection with HIV, precluding the use of alemtuzumab or cladribine
• Hypersensitivity reaction to natalizumab, precluding the use of natalizumab
• Current or past diagnosis of progressive multifocal leukoencephalopathy (PML), precluding the use of natalizumab, fingolimod, or dimethyl fumarate
• Severe hepatic impairment, precluding the use of fingolimod, interferons, natalizumab and teriflunomide
• Positive tuberculosis screening requiring standard TB treatment prior to teriflunomide dosing
• Active hepatitis B infection, precluding the use of ocrelizumab
• CYP2C9*3/*3 genotype, precluding the use of siponimod
• Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure, precluding the use of siponimod
• Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has functioning pacemaker, precluding the use of siponimod
• Current malignancy, precluding the use of cladribine
• Pregnant women and men of reproductive potential who do not plan to use effective contraception during treatment and for six months after the last dose of each treatment course, precluding the use of cladribine
• Active chronic infections (e.g., hepatitis or tuberculosis), precluding the use of cladribine, alemtuzumab, or ocrelizumab
• History of hypersensitivity to cladribine, precluding the use of cladribine
• Women intending to breastfeed on a treatment day or for 10 days after the last dose, precluding the use of cladribine

In addition to these contraindications, post-marketing data (Avonex; Rebif; Betaseron; Extavia)57,60–62 have led many clinicians to avoid the use of interferon beta medications in individuals who are depressed or have a history of significant depression. Although several studies have found no increased frequency of depression in patients taking interferon beta medications compared with those not taking these medications, interferon beta medications may exacerbate or precipitate depression in some patients as warned in the FDA prescribing information.291–294

Other co-morbid conditions may impact use of a particular disease-modifying therapeutic agent in individual circumstances compromising safety, efficacy or tolerability and necessitating access to an alternative option.

6. **Because severity of disease varies at onset – with some adults experiencing early aggressive disease – patients and their treating clinicians need access to all available options**

Although MS remains a highly unpredictable disease, certain clinical and MRI outcomes seem to be associated with a higher risk of disease progression:

• Scalfari and colleagues found that time to Expanded Disability Status Scale (EDSS) 3 highly and independently predicted time to EDSS 6, 8 and 10. The same group found that higher early relapse frequencies and shorter first inter-attack intervals increased the probability of – and hastened conversion to – secondary progression, and that although long-term outcomes were highly variable, some individuals who experienced frequent relapses and/or accumulated a large number of focal lesions on T2 MRI within the first five years were at greater risk of disability.113
• Fisniku and colleagues97 found lesion volume and its change at earlier time points to be correlated with disability after 20 years. In their study, lesion volume increased for at least 20 years in relapse-onset MS and the rate of lesion growth was three times higher in those who developed secondary progression than in those who remained relapsing-remitting.
• A prospective study in British Columbia that utilized three possible criteria for aggressive MS – confirmed Expanded Disability Status Scale (EDSS) ≥6 within five years of MS onset; confirmed EDSS ≥6 by age 40; and secondary progressive MS within three years of a relapsing-onset course –
identified aggressive MS in 4-14 percent of people depending on the definition used. Although the majority were males and those with PPMS, there were also a significant number of female patients and patients with RRMS.

- In a retrospective database study of aggressive onset MS, defined as two or more relapses in the year after onset and two or more Gd-enhancing lesions on MRI or one relapse if resulting in an EDSS of 3 along with two or more Gd-enhancing lesions, those patients who received or were switched to one of the following therapies – natalizumab, rituximab, alemtuzumab or cyclophosphamide – maintained a NEDA status during the 54-month mean duration of follow-up.

- Utilizing a different definition of aggressive MS that requires one or more of the following features, Rush and colleagues recommend more aggressive treatment agents to manage this challenging group of patients.

  - EDSS of four within five years of onset;
  - Multiple (>2) relapses with incomplete resolution within the past year;
  - More than two MRI studies showing new or enlarging T2 lesions or Gd-enhancing lesions despite treatment;
  - No response to therapy with one or more DMTs for up to one year.

Given these findings, patients with highly inflammatory and potentially aggressive disease may determine with their treating clinician that the benefit-to-risk ratio warrants starting or switching to a therapy with a higher potency and risk profile.

In fact, the 2018 AAN Guideline states as a Level B recommendation that “Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with highly active MS.”

Data also support the use of mitoxantrone. However, as noted previously, mitoxantrone is seldom prescribed because of its high risk profile. The 2018 AAN Guideline states as a level B recommendation that “Because of the high frequency of severe AEs, clinicians should not prescribe mitoxantrone to people with MS unless the potential therapeutic benefits greatly outweigh the risks.” Refer to AAN.com/guidelines.

7. Some children experience very active disease from onset

As previously mentioned, some children may experience very active disease that does not respond to the medications generally considered to be first-line treatment options for pediatric-onset MS.

8. African Americans and Hispanics appear to have more active disease

Several studies have now pointed to a more active disease course in African Americans and Hispanics with MS.

- In a multicenter study of retinal damage and vision loss, African Americans with MS were found to have accelerated damage compared to Caucasian MS patients, suggesting a more aggressive inflammatory disease course.
- In a different cohort, primary progressive MS was more common in African American patients, as was cerebellar dysfunction and a more rapid progression of disability.
- Compared to Caucasians, African American patients have also been found to have a greater likelihood of developing opticospinal MS and transverse myelitis and have a more aggressive course.
- More than one study has shown increased lesion volumes in African Americans, with one also showing more tissue damage.
- Given that there are also preliminary indications that African Americans may not respond as well to some of the available disease-modifying therapies, it is essential for African American patients and their clinicians to have access to the full range of treatment options in the event that one or another does not provide sufficient benefit.
• Hispanics as well as African Americans could be at greater risk of greater disease burden early in the disease course, while also facing greater barriers to care.26–29
• Hispanics, along with African Americans and Asians, are more likely to develop opticospinal MS than Caucasians, often leading to greater ambulatory disability.30

9. People who for one reason or another are not adhering to a treatment regimen need access to other treatment options.

In a retrospective cohort study of people starting treatment with interferon beta or glatiramer acetate, only 30-40 percent were adherent to treatment after two years.305 People who do not adhere to their treatment regimen are unlikely to receive the full benefit of the treatment.306,307 Factors associated with non-adherence include:
• Perceived lack of efficacy in relation to expectations307,308
• Route of administration309,310
• Perceived risks308,311,312
• Tolerability issues with self-injectable medications, including flu-like symptoms and injection-site reactions313–316
• Length of time on treatment312
• Costs317
• Psychosocial factors, including coping style,318 mood,319,320 and “forgetting”312,315,316

Addressing adherence issues begins with identifying the non-adherent patient so that the cause(s) can be addressed. In some instances, this may require an alternative treatment option that is likely to enhance the person’s ability to adhere to the treatment plan.

Under certain circumstances, other off-label agents may be needed to modify the disease course

For all the same reasons that clinicians and their patients need access to the full range of approved disease-modifying therapies, they may also need to turn to non-approved options that have demonstrated efficacy in people with MS (see Appendix C for further information about these off-label options).

CONCLUSIONS REGARDING THE NEEDS OF PEOPLE WITH MS
Although there is still much that we do not fully understand about the pathophysiology of MS, the last 20 years have provided a significant number of treatment options that improve prognosis and quality of life for people with MS. Furthermore, the growing body of evidence highlights the importance of early and ongoing access to and treatment with disease-modifying therapies.

Treatment Considerations
• Initiation of treatment with an FDA-approved disease-modifying therapy is recommended:
  - As soon as possible following a diagnosis of relapsing multiple sclerosis, regardless of the person’s age. Relapsing MS includes:
    ▪ clinically isolated syndrome (CIS): People with a first clinical event and MRI features consistent with MS in whom other possible causes have been excluded
    ▪ relapsing-remitting MS
    ▪ active secondary progressive MS with clinical relapses or inflammatory activity on MRI.
  - For individuals with primary progressive multiple sclerosis, with an agent approved for this phenotype
• Clinicians should consider prescribing a high efficacy medication such as alemtuzumab, cladribine, fingolimod, natalizumab or ocrelizumab for newly diagnosed individuals with highly active MS.
• Clinicians should also consider prescribing a high efficacy medication for individuals who have breakthrough activity on another disease-modifying therapy, regardless of the number of previously used agents.
• Treatment with a given disease-modifying medication should be continued indefinitely unless any of the following occur (in which case an alternative disease-modifying therapy should be considered):
- Sub-optimal treatment response as determined by the individual and his or her treating clinician
- Intolerable side effects, including significant laboratory abnormalities
- Inadequate adherence to the treatment regimen
- Availability of a more appropriate treatment option
- The healthcare provider and patient determine that the benefits no longer outweigh the risks

- Movement from one disease-modifying therapy to another should occur only for medically appropriate reasons as determined by the treating clinician and patient.
- When evidence of additional clinical or MRI activity while on consistent treatment suggests a sub-optimal response, an alternative regimen (e.g., different mechanism of action) should be considered to optimize therapeutic benefit.
- The factors affecting choice of therapy at any point in the disease course are complex and most appropriately analyzed and addressed through a shared decision-making process between the individual and his or her treating clinician. Neither an arbitrary restriction of choice nor a mandatory escalation therapy approach is supported by data.

**Access Considerations**

- MS clinical phenotypes may respond differently to different disease-modifying therapies.
- Due to significant variability in the MS population, people with MS and their treating clinicians require access to the full range of treatment options for several reasons:
  - Different mechanisms of action allow for treatment change in the event of a sub-optimal response
  - Potential contraindications limit options for some individuals
  - Risk tolerance varies among people with MS and their treating clinicians
  - Route of delivery and side effects may affect adherence and quality of life
  - Individual differences related to tolerability and adherence may necessitate access to different medications within the same class
  - Pregnancy and breastfeeding limit the available options
- Individuals’ access to treatment should not be limited by their frequency of relapses, level of disability, or personal characteristics such as age, sex or ethnicity
- Absence of relapses while on treatment is a characteristic of treatment effectiveness and should not be considered a justification for discontinuation of treatment
- Treatment should not be withheld to allow for determination of coverage by payers as this puts the patient at risk for recurrent disease activity
REFERENCES


ECTRIMS2017/199999/mitchell.t.wallin.the.prevalence.of.multiple.sclerosis.in.the.united.states.a.html


133. Langdon D, Benedict R, Wicklein EM, Fredrikson S. *Report of Cognitive Difficulties by Clinically Isolated Syndrome Patients and Careers: The Multiple Sclerosis Neuropsychological Questionnaire Data from the CogniCIS Baseline Cohort; Abstract P406*. Dusseldorf: 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS); 2009.


APPENDICES
APPENDIX A: Multiple Sclerosis Disease Courses 2013 Revisions

In 2013, the International Advisory Committee on Clinical Trials of MS updated the disease course descriptions that were first published in 1996 (Lublin & Reingold, 1996), based on advances in the understanding of the disease process in MS and in MRI technology. The updated disease courses are clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS.

Clinically Isolated Syndrome (CIS) – a first episode of inflammatory demyelination in the central nervous system that could become MS if dissemination in time and space are established.

According to the 2017 revisions to the diagnostic criteria for MS, the diagnosis of MS in a patient with CIS (with evidence of > 2 lesions) can be made when establishing dissemination in time – when there is an additional clinical attack; or simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; or new T2 or enhancing MRI lesion compared to baseline scan (without regard to timing of baseline scan); or CSF-specific (i.e., not in serum) oligoclonal bands.

In a patient with CIS (with objective clinical evidence of 1 lesion), the diagnosis can be made if dissemination in space and dissemination in time are established. Dissemination in space would be established by an additional attack implicating a different CNS site or > 1 MS-typical symptomatic or asymptomatic T2 lesions in > 2 areas of the CNS. Dissemination in time would be established by when there is an additional clinical attack; or simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; or new T2 or enhancing MRI lesion compared to baseline scan (without regard to timing of baseline scan); or CSF-specific (i.e., not in serum) oligoclonal bands.

Continue onto the following pages for text and graphics describing the other disease courses.

---


Relapsing-Remitting MS (RRMS) – episodes of acute worsening of neurologic functioning (new symptoms or worsening of existing symptoms) with total or partial recovery and no apparent progression of disease. RRMS can be further characterized as:

Active – showing evidence of new relapses, new gadolinium-enhancing lesions and/or new or enlarging T2 lesions on MRI over a specified time OR

Not active – showing no evidence of disease activity AND

Worsening – increased disability confirmed over a specified time following a relapse OR

Stable – no evidence of increasing disability over a specified time following a relapse
Primary Progressive MS (PPMS) – steadily worsening neurologic function (accumulation of disability) from the onset of symptoms without initial relapses of remission. PPMS can be further characterized as: Active – showing evidence of new relapses, new gadolinium-enhancing lesions and/or new or enlarging T2 lesions on MRI over a specified time OR Not active – showing no evidence of disease activity AND With progression – evidence of disease worsening on an objective measure of change, confirmed over a specified time, with or without relapses OR Without progression – no evidence of disease worsening on an objective measure of change over a specified time

PPMS

- Active (relapse or new MRI activity) with progression
- Not active without progression (stable)
- Not active with progression
- Active without progression
- New MRI activity
Secondary Progressive MS (SPMS) – following an initial relapsing-remitting course, the disease becomes more steadily progressive, with or without relapses. SPMS can be further characterized as:

**Active** – showing evidence of new relapses, new gadolinium-enhancing lesions and/or new enlarging T2 lesions on MRI over a specified time **OR**

**Not active** – showing no evidence of disease activity **AND**

**With progression** – evidence of disease worsening on an objective measure of change, confirmed over a specified time, with or without relapses **OR**

**Without progression** – no evidence of disease worsening on an objective measure of change over a specified time
### 2017 McDonald Criteria for the Diagnosis of Multiple Sclerosis

**CLINICAL PRESENTATION**

**ADDITIONAL DATA NEEDED TO MAKE MS DIAGNOSIS**

---

- **...in a person with a typical attack/CIS at onset**
  - (see KEY below for definitions)
  - **• ≥2 attacks and objective clinical evidence of ≥2 lesions**
  - **• ≥2 attacks and objective clinical evidence of ≥1 lesion with historical evidence of prior attack involving lesions in different location**
  - **• ≥2 attacks and objective clinical evidence of ≥1 lesion**
  - **• 1 attack and objective clinical evidence of ≥2 lesions**

- **None. Dissemination in space (DIS) and dissemination in time (DIT) have been met.**

- **One of these criteria:**
  - **- DIS: additional clinical attack implicating different CNS site**
  - **- DIS: ≥1 symptomatic or asymptomatic MS-typical T2 lesions in ≥2 areas of CNS: periventricular, juxtacortical/cortical, infratentorial or spinal cord**

- **One of these criteria:**
  - **- DIT: additional clinical attack**
  - **- DIT: simultaneous presence of both enhancing and non-enhancing symptomatic or asymptomatic MS-typical MRI lesions**
  - **- DIT: new T2 or enhancing MRI lesion compared to baseline scan (without regard to timing of baseline scan)**
  - **- CSF-specific (i.e. not in serum) oligoclonal bands**

---

*Color coding: revisions compared to previous McDonald Criteria*

**KEY:**
- **CIS:** clinically isolated syndrome
- **CNS:** central nervous system
- **CSF:** cerebrospinal fluid
- **DIS:** dissemination in space
- **DIT:** dissemination in time
- **T2 lesion:** hyperintense lesion on T2-weighted MRI


---

### 2017 McDonald Criteria for the Diagnosis of Multiple Sclerosis (continued)

**CLINICAL PRESENTATION**

**ADDITIONAL DATA NEEDED TO MAKE MS DIAGNOSIS**

---

- **...in a person with a typical attack/CIS at onset (continued)**
  - (see KEY on reverse for definitions)
  - **• 1 attack and objective clinical evidence of ≥1 lesion**

- **One of these criteria:**
  - **- DIS: additional clinical attack implicating different CNS site**
  - **- DIS: ≥1 MS-typical symptomatic or asymptomatic T2 lesions in ≥2 areas of CNS: periventricular, juxtacortical/cortical, infratentorial or spinal cord**
  - **AND**
  - **One of these criteria:**
  - **- DIT: additional clinical attack**
  - **- DIT: simultaneous presence of both enhancing and non-enhancing symptomatic or asymptomatic MS-typical MRI lesions**
  - **- DIT: by new T2 or enhancing MRI lesion compared to baseline scan (without regard to timing of baseline scan)**
  - **- CSF-specific (i.e. not in serum) oligoclonal bands**

---

- **...in a person with progression of disability from onset**

- **• progression from onset**
  - **1 year of disability progression (retrospective or prospective)**
  - **AND**
  - **Two of these criteria:**
  - **- ≥1 symptomatic or asymptomatic MS-typical T2 lesions (periventricular, juxtacortical/cortical or infratentorial)**
  - **≥2 T2 spinal cord lesions**
  - **CSF-specific (i.e. not in serum) oligoclonal bands**

---

*The International Panel on Diagnosis of Multiple Sclerosis was convened under the auspices of the International Advisory Committee on Clinical Trials in MS, sponsored by the National MS Society and the European Committee for Treatment and Research in Multiple Sclerosis.*

*More resources for clinicians: [https://www.nationalmssociety.org/For-Professionals/Physicians](https://www.nationalmssociety.org/For-Professionals/Physicians)*

©2018 National Multiple Sclerosis Society 733 Third Avenue, New York, NY 10017-3288
APPENDIX C: Treatments Used Off-Label for Multiple Sclerosis

The U.S. Food and Drug Administration (FDA) has approved medications for the treatment of relapsing forms of MS, as well as two medications for active secondary progressive MS (SPMS) and one for primary progressive MS (PPMS). However, response to these medications is variable and each has contraindications, side effects and risks that restrict their use for some people. In addition, barriers to access may exist for some people with one or another of the approved medications. Over the past few decades, several medications have been prescribed for the treatment of MS that have FDA approval for diagnoses other than MS. For each of these agents, there is some, but often limited clinical trial evidence of efficacy in MS. The available information is summarized here. Information about hematopoietic stem cell transplantation is also provided.

Azathioprine (Imuran®)

Azathioprine is an oral immunosuppressant drug that targets activation, proliferation, and differentiation of both T and B lymphocytes. Azathioprine is FDA-approved for use in combination with other medications to prevent organ rejection after kidney transplant and for the treatment of active rheumatoid arthritis. It is used outside of FDA approval for conditions such as Crohn’s disease, ulcerative colitis, lupus, autoimmune hepatitis, neuromyelitis optica, myasthenia gravis and multiple sclerosis. Azathioprine has been used in MS for over 30 years; however, the results of clinical trials with this agent have been mixed.

- A meta-analysis of placebo-controlled, double-blind, randomized trials in MS concluded that azathioprine is probably effective in reducing relapses and may reduce the risk of progression.
- In a study comparing interferon beta-1a used alone vs. interferon beta-1a plus azathioprine or interferon beta-1a plus azathioprine and prednisone, no difference was found between the groups in annualized relapse rate, cumulative probability of sustained disability progression, change in percentage of brain volume loss or T2 lesion volume. Follow-up after six years of treatment yielded similar results.
- Lus and colleagues evaluated the impact of azathioprine plus interferon beta-1a in three groups of relapsing-remitting patients: 1) a group with no prior treatment; 2) a group with inadequate response to prior treatment with azathioprine; and 3) a group with inadequate response to prior treatment with interferon beta-1a. The combined treatment reduced the mean number of relapses in all three groups and reduced the mean Delta EDSS score in groups 2 and 3. The combined treatment also resulted in significantly reduced MRI activity.
- A small two-year pilot study of azathioprine combined with interferon beta-1b in patients with secondary progressive MS whose disease had not been adequately controlled with interferon beta-1b alone reported a reduction in annual relapse rate of about 50 percent in year 2, a significant trend for an increase in EDSS, a decrease in lesion load on MRI at 12 and 24 months and a significant improvement in neuropsychological testing after 24 months. The investigators concluded that the combination treatment was safe and generally well tolerated; however, they recommended strict clinical and laboratory monitoring during treatment with this combination.
- In an open-label pilot trial to evaluate the addition of oral azathioprine to interferon beta-1b in patients who had breakthrough disease on interferon beta-1b alone, patients had a 65 percent reduction in the number of Gd-enhancing lesions compared to their baseline values. A total WBC count less than 4800/mm³ was the best predictor of MRI response.
- In a single-blind study comparing azathioprine with interferon beta over one year, the proportion of relapse-free patients was greater in the azathioprine group and the mean EDSS was also improved in this group.

Azathioprine is approved to treat MS in parts of Europe.
Side effects and risks include abdominal pain, severe nausea, vomiting, loss of appetite, mouth sores/ulcers, increased risk of infection, hair loss, change in hair color and texture, and risk of malignancies and blood abnormalities. Azathioprine can cause fetal abnormalities.

**Cyclophosphamide (Cytoxan®)**

Cyclophosphamide is an alkylating agent related to nitrogen mustard that binds to DNA and disrupts cell replication. In MS, the treatment serves as a general immune suppressant impacting cell-mediated and humoral immunity. It is given intravenously or orally.

Cyclophosphamide is FDA-approved for the treatment of various types of cancers. It is used off-label to treat autoimmune conditions such as Wegener’s granulomatosis, myasthenia gravis, lupus, rheumatoid arthritis and multiple sclerosis.

Placebo-controlled trials in progressive MS populations with different dosing regimens have found no benefit over placebo. However, several trials in people with active relapsing MS have demonstrated a reduction in relapses, fewer new areas of CNS inflammation and a variable effect on disease worsening, highlighting the usefulness of cyclophosphamide in younger, inflammatory and less progressed patients.

- Monthly intravenous cyclophosphamide led to improvement and neurologic stability within six months, sustained for at least 18 months after treatment onset, in patients with rapidly deteriorating relapsing-remitting MS.
- In a combination trial of cyclophosphamide and interferon beta, with follow-up at 12 and 24 months, Reggio and colleagues found that the combination treatment halted disease progression in active, deteriorating MS patients who had received insufficient benefits from interferon beta alone.
- In a study of 10 patients with very active disease and severe frequent attacks who had not benefited from interferon beta alone, Patti and colleagues used pulsed cyclophosphamide to obtain a chronic lymphocytopenia, resulting in a marked and significant relapse reduction, improvement in disability and reduction of T2 burden of disease. Thirty-six months after discontinuation of cyclophosphamide, clinical and MRI benefits were maintained.
- In a randomized single-blind, parallel-group, multi-center trial, combination therapy using pulsed cyclophosphamide with methylprednisolone along with interferon beta-1a significantly decreased the number of Gd-enhancing lesions and slowed clinical activity in patients who had experienced active disease on interferon beta alone.

Side effects and risks include nausea, vomiting, hair thinning/loss, low white blood cell count, risk of infections, risk of cancers, infertility, and inflammation of the bladder with bleeding. Cyclophosphamide causes fetal abnormalities.

**Minocycline**

Minocycline is an oral tetracycline antibiotic that is FDA approved for the treatment of a number of different types of bacterial infection. It is used off-label as a treatment for rheumatoid arthritis.

Minocycline has also been studied in conditions such as osteoporosis, schizophrenia, cystic fibrosis and multiple sclerosis.

- In patients with RRMS, interferon beta-1a plus minocycline was found to be no more effective than interferon beta-1a plus placebo in time to first relapse, annualized relapse rate, number of new or enlarging T2 lesions on MRI, or change in brain volume.
- In patients with RRMS, minocycline plus glatiramer acetate was found to be safe and well-tolerated, and reduced the number of T1 gadolinium-enhanced lesions, the total number of new and enlarging T2 lesions, and the total T2 burden of disease compared to glatiramer acetate plus placebo.

Side effects and risks include gastrointestinal problems, liver damage, mild to severe skin conditions, respiratory problems, kidney toxicity, muscle and joint pain, blood cell abnormalities and central nervous
system disorders. Minocycline is a pregnancy category D medication, indicating potential for fetal abnormalities.

**Mycophenolate mofetil (Cellcept®)**
Mycophenolate mofetil is an immunosuppressant given by mouth twice daily that selectively inhibits an enzyme responsible for the de novo synthesis of the DNA nucleotide guanine within T-cells, B-cells and macrophages. It is FDA approved for preventing rejection in patients receiving organ transplants and is used off-label for lupus, certain types of skin diseases and immune system-related diseases, including multiple sclerosis.

- Mycophenolate mofetil has been studied in small, open-label trials as a monotherapy or in combination with interferon beta or glatiramer acetate and in two blinded, placebo-controlled pilot studies in combination with interferon beta-1a.

- Mycophenolate mofetil has also been compared with interferon beta-1a in a small randomized, blinded, parallel group pilot trial in patients with relapsing-remitting MS.

The results of these studies suggest that mycophenolate mofetil may reduce the annual number of MS relapses, limit new areas of CNS damage and may slow disease worsening, however additional studies are needed to confirm these benefits. Side effects and risks include increased risk of infection (including opportunistic infections such as PML), nausea, diarrhea, stomach pain, weakness, dizziness, difficulty sleeping, increased risk of skin cancer and lymphoma, stomach ulcers and bleeding, elevation in liver enzymes and jaundice. Mycophenolate mofetil can cause fetal death or malformations.

**Rituximab (Rituxan®)**
Rituximab is a chimeric monoclonal antibody that targets CD20 on the surface of B-lymphocytes, which are known to cause inflammation and damage in MS.
Rituximab is FDA approved for the treatment of several conditions including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and granulomatosis with polyangiitis, and microscopic polyangiitis. It has been used successfully off-label to treat neuromyelitis optica, multiple sclerosis, myasthenia gravis, autoimmune encephalitis, and autoimmune neuropathies and myopathies. Several clinical trials in MS have demonstrated that rituximab is effective in reducing clinical relapses and limiting new inflammation in the central nervous system.

- In a phase 2, double-blind, 48-week trial in relapsing-remitting MS, a single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks.

- A randomized, double-blind, placebo-controlled study of rituximab in primary progressive MS came close to meeting its endpoint, suggesting that selective B-cell depletion may slow disease progression in younger patients with inflammatory lesions.

- Rituximab was found to be more effective than fingolimod in reducing the risk of clinical relapses and contrast-enhancing lesions in stable relapsing-remitting MS patients who switch from natalizumab after becoming JC virus antibody positive.

- In a retrospective uncontrolled observational multicenter study that included relapsing-remitting, secondary progressive and primary progressive MS patients receiving different doses of rituximab, the treatment was generally well-tolerated, with a low incidence of serious side effects, and was effective in controlling relapses.

Rituximab is given by intravenous infusion. A common dosing regimen is two intravenous infusions separated by two weeks, repeated every six months.
Side effects and risks include infusion reactions, infections (including opportunistic infections such as PML), allergic reactions, headache, fatigue and anemia. Rituximab is a pregnancy category C.
Hematopoietic stem cell transplantation (HSCT)

HSCT uses autologous, hematopoietic stem cells, derived from the bone marrow or blood, to repopulate the body’s immune cells and stop the inflammatory process that contributes to active relapsing MS. While the procedure varies somewhat depending on the medical center and doctors who are performing it, the essential steps include: outpatient chemotherapy by intravenous infusion for up to 10 days to stimulate the production of bone marrow stem cells and promote their release into the blood; storage of stem cells from the blood for future use; inpatient chemotherapy for up to 11 days to suppress the body’s immune cells; infusion of stored stem cells into the bloodstream; administration of antibiotics to combat infection; immune reconstitution completed within three to six months.

- In a multicenter, single-group phase 2 trial involving 24 patients with aggressive relapsing MS that had not responded to other therapies, investigators reported a 69.6 percent MS activity-free survival rate at three years following transplantation, with no relapses and no Gd-enhancing lesions or new T2 lesions on 314 MRI sequential scans over a median follow-up of 6.7 years (range 3.9-12.7 years). The rate of brain atrophy decreased to the level expected in healthy controls and 35 percent of patients had a sustained improvement in EDSS. One patient died of transplantation-related complications resulting in liver failure; one patient required intensive hospital care for severe liver complications; all participants developed fevers typically associated with infections.

- In a 5-year multi-center study, 25 people with active relapsing MS that had not been controlled by disease-modifying therapies underwent HSCT with high-dose immunosuppressive therapy. After five years, 69 percent of participants remained free of disease activity and required no disease-modifying therapy. Reported side effects included blood cell reductions and infections.

- Other studies using a low-intensity lympho-ablative regimen or a non-myeloablative regimen designed to reduce toxicity, demonstrated some improvement in some trial participants, with fewer adverse events, leading investigators to conclude that these technique may not be optimal for individuals with highly aggressive disease or disease of long-standing.

Scolding and colleagues, on behalf of the attendees at the International Conference on Cell-Based Therapies for Multiple Sclerosis, concluded the following based on their review of I/AHSCT (Immunoaulation followed by autologous hematopoietic stem cell transplantation) studies:

- The available evidence suggests substantial efficacy in suppressing inflammatory disease activity; however, the benefit/risk/cost profile is not completely known.
- Patients most likely to benefit include those with active relapsing-remitting MS, ≤ 50 years of age, with ≤ 5 years disease duration, who are ambulatory and have ongoing disease despite disease-modifying therapy.
- Additional study is needed, particularly head-to-head comparisons with high efficacy disease-modifying agents.
- If HSCT is performed in clinical practice, safety and efficacy data should be collected, reported and published. However, the group strongly encouraged enrolling patients in ongoing clinical trials when available.
REFERENCES


THE MULTIPLE SCLEROSIS COALITION

The Multiple Sclerosis Coalition (MSC) was founded in 2005 by three independent multiple sclerosis organizations in an effort to work together to benefit individuals with MS. Since that time, the MSC has grown to nine member organizations, all of whom provide critical MS programs and services.

Vision: To improve the quality of life for those affected by MS through a collaborative national network of independent MS organizations.

Mission: To increase opportunities for cooperation and provide greater opportunity to leverage the effective use of resources for the benefit of the MS community.

The primary objectives of the MSC are to educate, advocate, collaborate and improve the efficiency of services for individuals with MS and those who are close to them. With so much on the horizon in terms of MS research, treatments, advocacy and symptom management, the MSC provides critical momentum to work together to enhance these exciting MS initiatives and to ensure this collective support continues.

Members:

Accelerated Cure Project for Multiple Sclerosis (ACP)
Accelerated Cure Project is a national nonprofit dedicated to curing MS by determining its causes. Our repository contains samples and data from people with MS and other demyelinating diseases. Samples are available to researchers who submit all data they generate back to the repository to be shared with others.
acceleratedcure.org | 781-487-0008

Can Do Multiple Sclerosis (Can Do MS)
As a national nonprofit organization, Can Do Multiple Sclerosis is a leading provider of innovative lifestyle empowerment programs that empower people with MS and their support partners to transform and improve their quality of life.
cando-ms.org | 800-367-3101

Consortium of Multiple Sclerosis Centers (CMSC)
The Consortium of MS Centers is the preeminent North American organization of MS healthcare professionals and researchers with a network of more than 11,000 healthcare clinicians and scientists committed to MS care. CMSC promotes sustained improvements in MS healthcare practice through clinical research, education and training, networking and targeted advocacy efforts.
mscare.org | 201-487-1050

International Organization of Multiple Sclerosis Nurses (IOMSN)
The International Organization of Multiple sclerosis Nurses is the first and only international organization focused solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing – the IOMSN supports nurses in their continuing effort to offer HOPE.
iomsn.org | 201-487-1050

Multiple Sclerosis Association of America (MSAA)
The Multiple Sclerosis Association of America is a leading resource for the entire MS community, improving lives today through vital services and support. MSAA provides free programs and services, such as: a helpline; award-winning publications; website featuring educational videos and research updates; shared-management tools to assist the MS community in managing their MS; safety and
mobility equipment; cooling accessories for heat-sensitive individuals; educational events and activities; MRI funding and insurance advocacy; as well as other services.

mymsaa.org | 800-532-7667

Multiple Sclerosis Foundation (MSFocus)
The Multiple Sclerosis Foundation, known in the MS community as MS Focus, is a nonprofit organization focused on providing free services that address the critical needs of people with MS and their families and on helping them maintain the best quality of life. MS presents physical, emotional, and financial challenges families must face. MS Focus is here to provide the support, education, and assistance needed to adapt to these challenging circumstances. Our primary focus is on providing individuals with MS the help they need to maintain their health and well-being, to continue to be productive and independent, and to keep a roof over their heads and a safe environment in their home.

msfocus.org | 800-225-6495

National Multiple Sclerosis Society
The National MS Society mobilizes people and resources so that everyone affected by multiple sclerosis can live their best lives as we stop MS in its tracks, restore what has been lost and end MS forever.
nationalMSsociety.org | 800-344-4867

United Spinal Association
The United Spinal Association is a national VA-authorized non-profit organization committed to providing service programs and advocacy for those living with spinal cord injuries and disorders (SCI/D) such as multiple sclerosis, amyotrophic lateral sclerosis, and spina bifida. There are more than a million individuals throughout the country with SCI/D to whom the Association’s work is dedicated. The United Spinal Association has close to 40,000 members, 30 chapters, close to 200 support groups nationwide and publishes the New Mobility and Life Action magazines. Throughout its history, United Spinal Association has devoted its energies, talents and programs to improving the quality of life for Americans with spinal cord injuries and disorders.
unitedspinal.org | 718-803-3782

Associate Member:

MS Views and News (MSVN)
MS Views and News is dedicated to the global collection and distribution of information concerning MS. Through partnering relationships, MSVN provides education, advocacy and service to empower and enhance the quality of life of the MS community.
msviews.org | 888-871-1664

© 2019: The Multiple Sclerosis Coalition